CN1630709A - 人胰高血糖素样多肽-1模拟物和它们在治疗糖尿病和相关状况中的应用 - Google Patents
人胰高血糖素样多肽-1模拟物和它们在治疗糖尿病和相关状况中的应用 Download PDFInfo
- Publication number
- CN1630709A CN1630709A CNA028205588A CN02820558A CN1630709A CN 1630709 A CN1630709 A CN 1630709A CN A028205588 A CNA028205588 A CN A028205588A CN 02820558 A CN02820558 A CN 02820558A CN 1630709 A CN1630709 A CN 1630709A
- Authority
- CN
- China
- Prior art keywords
- bip
- methyl
- alpha
- ethyl
- phe
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000011282 treatment Methods 0.000 title claims abstract description 18
- 206010012601 diabetes mellitus Diseases 0.000 title claims description 13
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical class C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 title abstract description 4
- 101500028774 Homo sapiens Glucagon-like peptide 1 Proteins 0.000 title abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 214
- 230000000694 effects Effects 0.000 claims abstract description 13
- -1 heterocyclic radical Chemical class 0.000 claims description 771
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 354
- 229910052731 fluorine Inorganic materials 0.000 claims description 353
- 239000011737 fluorine Substances 0.000 claims description 353
- 229960005190 phenylalanine Drugs 0.000 claims description 241
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 240
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 claims description 210
- 239000001301 oxygen Substances 0.000 claims description 164
- 229910052760 oxygen Inorganic materials 0.000 claims description 164
- 125000000217 alkyl group Chemical group 0.000 claims description 158
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 148
- 229910052799 carbon Inorganic materials 0.000 claims description 135
- 125000000539 amino acid group Chemical group 0.000 claims description 124
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims description 117
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 116
- 125000001424 substituent group Chemical group 0.000 claims description 110
- 229920001184 polypeptide Polymers 0.000 claims description 105
- 229910052739 hydrogen Inorganic materials 0.000 claims description 97
- 239000001257 hydrogen Substances 0.000 claims description 96
- 125000003118 aryl group Chemical group 0.000 claims description 76
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 67
- 125000001072 heteroaryl group Chemical group 0.000 claims description 65
- 238000000034 method Methods 0.000 claims description 63
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 59
- 150000002431 hydrogen Chemical class 0.000 claims description 54
- 229940024606 amino acid Drugs 0.000 claims description 53
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims description 53
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 51
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 50
- 235000001014 amino acid Nutrition 0.000 claims description 45
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims description 44
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-Histidine Natural products OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 43
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 42
- 150000001413 amino acids Chemical class 0.000 claims description 38
- 125000004181 carboxyalkyl group Chemical group 0.000 claims description 38
- ZRALSGWEFCBTJO-UHFFFAOYSA-N anhydrous guanidine Natural products NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 claims description 36
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 35
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 35
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 34
- CKLJMWTZIZZHCS-UWTATZPHSA-N D-aspartic acid Chemical compound OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 claims description 33
- 125000005160 aryl oxy alkyl group Chemical group 0.000 claims description 33
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 claims description 31
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 claims description 31
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 31
- 125000000623 heterocyclic group Chemical group 0.000 claims description 29
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 28
- 229910052736 halogen Inorganic materials 0.000 claims description 28
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 27
- 150000002367 halogens Chemical class 0.000 claims description 27
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 27
- 239000000460 chlorine Substances 0.000 claims description 26
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 26
- HYOWVAAEQCNGLE-SNVBAGLBSA-N (2r)-2-azaniumyl-2-methyl-3-phenylpropanoate Chemical compound [O-]C(=O)[C@@]([NH3+])(C)CC1=CC=CC=C1 HYOWVAAEQCNGLE-SNVBAGLBSA-N 0.000 claims description 25
- HYOWVAAEQCNGLE-JTQLQIEISA-N alpha-methyl-L-phenylalanine Chemical compound OC(=O)[C@](N)(C)CC1=CC=CC=C1 HYOWVAAEQCNGLE-JTQLQIEISA-N 0.000 claims description 25
- 229910052801 chlorine Inorganic materials 0.000 claims description 25
- 229960002885 histidine Drugs 0.000 claims description 25
- 125000002252 acyl group Chemical group 0.000 claims description 24
- 239000003814 drug Substances 0.000 claims description 24
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 24
- 229960004441 tyrosine Drugs 0.000 claims description 23
- 125000003545 alkoxy group Chemical group 0.000 claims description 22
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 20
- UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 claims description 20
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Natural products C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 19
- 150000001875 compounds Chemical class 0.000 claims description 19
- 229960001153 serine Drugs 0.000 claims description 19
- 229960005261 aspartic acid Drugs 0.000 claims description 18
- 229910052740 iodine Inorganic materials 0.000 claims description 18
- 239000011630 iodine Substances 0.000 claims description 18
- 125000004103 aminoalkyl group Chemical group 0.000 claims description 17
- 125000005358 mercaptoalkyl group Chemical group 0.000 claims description 17
- 239000004473 Threonine Substances 0.000 claims description 16
- 125000004171 alkoxy aryl group Chemical group 0.000 claims description 16
- 125000000304 alkynyl group Chemical group 0.000 claims description 16
- 125000003368 amide group Chemical group 0.000 claims description 16
- 125000004104 aryloxy group Chemical group 0.000 claims description 16
- 125000005553 heteroaryloxy group Chemical group 0.000 claims description 16
- 229960002898 threonine Drugs 0.000 claims description 16
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 claims description 15
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 15
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 15
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 claims description 14
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 13
- 125000005392 carboxamide group Chemical group NC(=O)* 0.000 claims description 13
- 229960002989 glutamic acid Drugs 0.000 claims description 13
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 13
- UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 claims description 12
- 239000004471 Glycine Substances 0.000 claims description 12
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 12
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims description 12
- 125000004423 acyloxy group Chemical group 0.000 claims description 12
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 12
- 230000029936 alkylation Effects 0.000 claims description 12
- 238000005804 alkylation reaction Methods 0.000 claims description 12
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 12
- 150000001408 amides Chemical group 0.000 claims description 12
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims description 12
- CFHIDWOYWUOIHU-UHFFFAOYSA-N oxomethyl Chemical compound O=[CH] CFHIDWOYWUOIHU-UHFFFAOYSA-N 0.000 claims description 12
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 claims description 12
- 229910019142 PO4 Inorganic materials 0.000 claims description 11
- 239000002253 acid Substances 0.000 claims description 11
- 125000002947 alkylene group Chemical group 0.000 claims description 11
- 230000015572 biosynthetic process Effects 0.000 claims description 11
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 11
- 239000010452 phosphate Substances 0.000 claims description 11
- 229960002429 proline Drugs 0.000 claims description 11
- 229960004799 tryptophan Drugs 0.000 claims description 11
- AYFVYJQAPQTCCC-STHAYSLISA-N D-threonine Chemical compound C[C@H](O)[C@@H](N)C(O)=O AYFVYJQAPQTCCC-STHAYSLISA-N 0.000 claims description 10
- 229930182822 D-threonine Natural products 0.000 claims description 10
- 108060003199 Glucagon Proteins 0.000 claims description 10
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 10
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 10
- 229930195722 L-methionine Natural products 0.000 claims description 10
- SNDPXSYFESPGGJ-UHFFFAOYSA-N L-norVal-OH Natural products CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 claims description 10
- 229930182821 L-proline Natural products 0.000 claims description 10
- 125000000769 L-threonyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])[C@](O[H])(C([H])([H])[H])[H] 0.000 claims description 10
- 125000004688 alkyl sulfonyl alkyl group Chemical group 0.000 claims description 10
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 claims description 10
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea group Chemical group NC(=O)N XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 10
- KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical group NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 claims description 9
- 102000051325 Glucagon Human genes 0.000 claims description 9
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 9
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 9
- 229960004666 glucagon Drugs 0.000 claims description 9
- 239000000018 receptor agonist Substances 0.000 claims description 9
- 229940044601 receptor agonist Drugs 0.000 claims description 9
- 102000005962 receptors Human genes 0.000 claims description 9
- 108020003175 receptors Proteins 0.000 claims description 9
- VOIMMWFAFDNMOX-SFHVURJKSA-N (2S)-2-amino-3-(4-naphthalen-1-ylphenyl)propanoic acid Chemical compound C1=CC(C[C@H](N)C(O)=O)=CC=C1C1=CC=CC2=CC=CC=C12 VOIMMWFAFDNMOX-SFHVURJKSA-N 0.000 claims description 8
- 241000790917 Dioxys <bee> Species 0.000 claims description 8
- 102000004877 Insulin Human genes 0.000 claims description 8
- 108090001061 Insulin Proteins 0.000 claims description 8
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 8
- 230000002152 alkylating effect Effects 0.000 claims description 8
- 150000002148 esters Chemical class 0.000 claims description 8
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 8
- 150000001414 amino alcohols Chemical class 0.000 claims description 7
- HAMNKKUPIHEESI-UHFFFAOYSA-N aminoguanidine Chemical compound NNC(N)=N HAMNKKUPIHEESI-UHFFFAOYSA-N 0.000 claims description 7
- 235000010290 biphenyl Nutrition 0.000 claims description 7
- 125000005326 heteroaryloxy alkyl group Chemical group 0.000 claims description 7
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims description 7
- COLNVLDHVKWLRT-MRVPVSSYSA-N D-phenylalanine Chemical compound OC(=O)[C@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-MRVPVSSYSA-N 0.000 claims description 6
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 6
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 6
- 239000006035 Tryptophane Substances 0.000 claims description 6
- 239000003153 chemical reaction reagent Substances 0.000 claims description 6
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen(.) Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 6
- 229930192474 thiophene Natural products 0.000 claims description 6
- ZUTQNQZOJMPXNQ-BYPYZUCNSA-N (2s)-4-sulfanylidenepyrrolidine-2-carboxylic acid Chemical compound OC(=O)[C@@H]1CC(=S)CN1 ZUTQNQZOJMPXNQ-BYPYZUCNSA-N 0.000 claims description 5
- QDGAVODICPCDMU-UHFFFAOYSA-N 2-amino-3-[3-[bis(2-chloroethyl)amino]phenyl]propanoic acid Chemical compound OC(=O)C(N)CC1=CC=CC(N(CCCl)CCCl)=C1 QDGAVODICPCDMU-UHFFFAOYSA-N 0.000 claims description 5
- 239000004475 Arginine Substances 0.000 claims description 5
- MTCFGRXMJLQNBG-UWTATZPHSA-N D-Serine Chemical compound OC[C@@H](N)C(O)=O MTCFGRXMJLQNBG-UWTATZPHSA-N 0.000 claims description 5
- 229930195711 D-Serine Natural products 0.000 claims description 5
- 229930182832 D-phenylalanine Natural products 0.000 claims description 5
- FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 claims description 5
- 125000000570 L-alpha-aspartyl group Chemical group [H]OC(=O)C([H])([H])[C@]([H])(N([H])[H])C(*)=O 0.000 claims description 5
- 125000002842 L-seryl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])O[H] 0.000 claims description 5
- 230000003178 anti-diabetic effect Effects 0.000 claims description 5
- 239000003472 antidiabetic agent Substances 0.000 claims description 5
- 229960003121 arginine Drugs 0.000 claims description 5
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 claims description 5
- 125000005982 diphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 5
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims description 5
- 230000035876 healing Effects 0.000 claims description 5
- 229960004452 methionine Drugs 0.000 claims description 5
- 230000011987 methylation Effects 0.000 claims description 5
- 238000007069 methylation reaction Methods 0.000 claims description 5
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 claims description 5
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 4
- 239000005864 Sulphur Substances 0.000 claims description 4
- 230000008859 change Effects 0.000 claims description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 4
- 230000001404 mediated effect Effects 0.000 claims description 4
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 4
- 230000019491 signal transduction Effects 0.000 claims description 4
- 208000011580 syndromic disease Diseases 0.000 claims description 4
- CYZKJBZEIFWZSR-ZCFIWIBFSA-N (2r)-3-(1h-imidazol-5-yl)-2-(methylamino)propanoic acid Chemical compound CN[C@@H](C(O)=O)CC1=CN=CN1 CYZKJBZEIFWZSR-ZCFIWIBFSA-N 0.000 claims description 3
- HWAKOCNTLFYOFR-ZDUSSCGKSA-N (2s)-2-amino-3-(4-pyridin-3-ylphenyl)propanoic acid Chemical compound C1=CC(C[C@H](N)C(O)=O)=CC=C1C1=CC=CN=C1 HWAKOCNTLFYOFR-ZDUSSCGKSA-N 0.000 claims description 3
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 claims description 3
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 claims description 3
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 3
- HNDVDQJCIGZPNO-RXMQYKEDSA-N D-histidine Chemical compound OC(=O)[C@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-RXMQYKEDSA-N 0.000 claims description 3
- 229930195721 D-histidine Natural products 0.000 claims description 3
- 208000002249 Diabetes Complications Diseases 0.000 claims description 3
- 206010012655 Diabetic complications Diseases 0.000 claims description 3
- 206010060378 Hyperinsulinaemia Diseases 0.000 claims description 3
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 3
- 125000002066 L-histidyl group Chemical group [H]N1C([H])=NC(C([H])([H])[C@](C(=O)[*])([H])N([H])[H])=C1[H] 0.000 claims description 3
- CYZKJBZEIFWZSR-LURJTMIESA-N N(alpha)-methyl-L-histidine Chemical compound CN[C@H](C(O)=O)CC1=CNC=N1 CYZKJBZEIFWZSR-LURJTMIESA-N 0.000 claims description 3
- XUYPXLNMDZIRQH-LURJTMIESA-N N-acetyl-L-methionine Chemical compound CSCC[C@@H](C(O)=O)NC(C)=O XUYPXLNMDZIRQH-LURJTMIESA-N 0.000 claims description 3
- 208000008589 Obesity Diseases 0.000 claims description 3
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 3
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 3
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 3
- 239000000883 anti-obesity agent Substances 0.000 claims description 3
- 229940125710 antiobesity agent Drugs 0.000 claims description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 3
- 235000003704 aspartic acid Nutrition 0.000 claims description 3
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 3
- 210000004369 blood Anatomy 0.000 claims description 3
- 239000008280 blood Substances 0.000 claims description 3
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 3
- JBKVHLHDHHXQEQ-UHFFFAOYSA-N epsilon-caprolactam Chemical compound O=C1CCCCCN1 JBKVHLHDHHXQEQ-UHFFFAOYSA-N 0.000 claims description 3
- 201000001421 hyperglycemia Diseases 0.000 claims description 3
- 230000003451 hyperinsulinaemic effect Effects 0.000 claims description 3
- 201000008980 hyperinsulinism Diseases 0.000 claims description 3
- 229930182817 methionine Natural products 0.000 claims description 3
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 claims description 3
- 235000020824 obesity Nutrition 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 230000001225 therapeutic effect Effects 0.000 claims description 3
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 claims description 2
- 201000001320 Atherosclerosis Diseases 0.000 claims description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 2
- 206010020772 Hypertension Diseases 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 claims description 2
- 208000012902 Nervous system disease Diseases 0.000 claims description 2
- 208000017442 Retinal disease Diseases 0.000 claims description 2
- 206010038923 Retinopathy Diseases 0.000 claims description 2
- 229940100389 Sulfonylurea Drugs 0.000 claims description 2
- 229940000635 beta-alanine Drugs 0.000 claims description 2
- 238000011161 development Methods 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 235000011187 glycerol Nutrition 0.000 claims description 2
- 229960002449 glycine Drugs 0.000 claims description 2
- 230000001631 hypertensive effect Effects 0.000 claims description 2
- 208000006575 hypertriglyceridemia Diseases 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 229940125396 insulin Drugs 0.000 claims description 2
- 150000002632 lipids Chemical class 0.000 claims description 2
- 230000029663 wound healing Effects 0.000 claims description 2
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical group [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 claims 48
- NSTPXGARCQOSAU-VIFPVBQESA-N N-formyl-L-phenylalanine Chemical compound O=CN[C@H](C(=O)O)CC1=CC=CC=C1 NSTPXGARCQOSAU-VIFPVBQESA-N 0.000 claims 23
- 239000003112 inhibitor Substances 0.000 claims 5
- 239000003795 chemical substances by application Substances 0.000 claims 4
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 claims 2
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 claims 2
- 230000000879 anti-atherosclerotic effect Effects 0.000 claims 2
- 230000003579 anti-obesity Effects 0.000 claims 2
- 239000002220 antihypertensive agent Substances 0.000 claims 2
- 229940030600 antihypertensive agent Drugs 0.000 claims 2
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical group CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 claims 2
- DHHVAGZRUROJKS-UHFFFAOYSA-N phentermine Chemical compound CC(C)(N)CC1=CC=CC=C1 DHHVAGZRUROJKS-UHFFFAOYSA-N 0.000 claims 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims 2
- 229960002855 simvastatin Drugs 0.000 claims 2
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 claims 2
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 claims 1
- FJLGEFLZQAZZCD-MCBHFWOFSA-N (3R,5S)-fluvastatin Chemical compound C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 FJLGEFLZQAZZCD-MCBHFWOFSA-N 0.000 claims 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 claims 1
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 claims 1
- BOVGTQGAOIONJV-BETUJISGSA-N 1-[(3ar,6as)-3,3a,4,5,6,6a-hexahydro-1h-cyclopenta[c]pyrrol-2-yl]-3-(4-methylphenyl)sulfonylurea Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1C[C@H]2CCC[C@H]2C1 BOVGTQGAOIONJV-BETUJISGSA-N 0.000 claims 1
- SWLAMJPTOQZTAE-UHFFFAOYSA-N 4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]benzoic acid Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(C(O)=O)C=C1 SWLAMJPTOQZTAE-UHFFFAOYSA-N 0.000 claims 1
- QBQLYIISSRXYKL-UHFFFAOYSA-N 4-[[4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]phenyl]methyl]-1,2-oxazolidine-3,5-dione Chemical compound CC=1OC(C=2C=CC=CC=2)=NC=1CCOC(C=C1)=CC=C1CC1C(=O)NOC1=O QBQLYIISSRXYKL-UHFFFAOYSA-N 0.000 claims 1
- NFFXEUUOMTXWCX-UHFFFAOYSA-N 5-[(2,4-dioxo-1,3-thiazolidin-5-yl)methyl]-2-methoxy-n-[[4-(trifluoromethyl)phenyl]methyl]benzamide Chemical compound C1=C(C(=O)NCC=2C=CC(=CC=2)C(F)(F)F)C(OC)=CC=C1CC1SC(=O)NC1=O NFFXEUUOMTXWCX-UHFFFAOYSA-N 0.000 claims 1
- IETKPTYAGKZLKY-UHFFFAOYSA-N 5-[[4-[(3-methyl-4-oxoquinazolin-2-yl)methoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione Chemical compound N=1C2=CC=CC=C2C(=O)N(C)C=1COC(C=C1)=CC=C1CC1SC(=O)NC1=O IETKPTYAGKZLKY-UHFFFAOYSA-N 0.000 claims 1
- 229940123324 Acyltransferase inhibitor Drugs 0.000 claims 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 claims 1
- PTQXTEKSNBVPQJ-UHFFFAOYSA-N Avasimibe Chemical compound CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1CC(=O)NS(=O)(=O)OC1=C(C(C)C)C=CC=C1C(C)C PTQXTEKSNBVPQJ-UHFFFAOYSA-N 0.000 claims 1
- 229940123208 Biguanide Drugs 0.000 claims 1
- RKWGIWYCVPQPMF-UHFFFAOYSA-N Chloropropamide Chemical compound CCCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1 RKWGIWYCVPQPMF-UHFFFAOYSA-N 0.000 claims 1
- 108010061846 Cholesterol Ester Transfer Proteins Proteins 0.000 claims 1
- 102000012336 Cholesterol Ester Transfer Proteins Human genes 0.000 claims 1
- CTENFNNZBMHDDG-UHFFFAOYSA-N Dopamine hydrochloride Chemical compound Cl.NCCC1=CC=C(O)C(O)=C1 CTENFNNZBMHDDG-UHFFFAOYSA-N 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- HTQBXNHDCUEHJF-XWLPCZSASA-N Exenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 HTQBXNHDCUEHJF-XWLPCZSASA-N 0.000 claims 1
- GGUVRMBIEPYOKL-WMVCGJOFSA-N GW 409544 Chemical compound C([C@H](NC(/C)=C\C(=O)C=1C=CC=CC=1)C(O)=O)C(C=C1)=CC=C1OCCC(=C(O1)C)N=C1C1=CC=CC=C1 GGUVRMBIEPYOKL-WMVCGJOFSA-N 0.000 claims 1
- FAEKWTJYAYMJKF-QHCPKHFHSA-N GlucoNorm Chemical compound C1=C(C(O)=O)C(OCC)=CC(CC(=O)N[C@@H](CC(C)C)C=2C(=CC=CC=2)N2CCCCC2)=C1 FAEKWTJYAYMJKF-QHCPKHFHSA-N 0.000 claims 1
- 102000004366 Glucosidases Human genes 0.000 claims 1
- 108010056771 Glucosidases Proteins 0.000 claims 1
- 229940122355 Insulin sensitizer Drugs 0.000 claims 1
- 102000000853 LDL receptors Human genes 0.000 claims 1
- 108010001831 LDL receptors Proteins 0.000 claims 1
- 229940086609 Lipase inhibitor Drugs 0.000 claims 1
- 239000000867 Lipoxygenase Inhibitor Substances 0.000 claims 1
- 229940122142 Lipoxygenase inhibitor Drugs 0.000 claims 1
- ZPXSCAKFGYXMGA-UHFFFAOYSA-N Mazindol Chemical compound N12CCN=C2C2=CC=CC=C2C1(O)C1=CC=C(Cl)C=C1 ZPXSCAKFGYXMGA-UHFFFAOYSA-N 0.000 claims 1
- 102100031545 Microsomal triglyceride transfer protein large subunit Human genes 0.000 claims 1
- IBAQFPQHRJAVAV-ULAWRXDQSA-N Miglitol Chemical compound OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO IBAQFPQHRJAVAV-ULAWRXDQSA-N 0.000 claims 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 claims 1
- 102000023984 PPAR alpha Human genes 0.000 claims 1
- 108010028924 PPAR alpha Proteins 0.000 claims 1
- 102000000536 PPAR gamma Human genes 0.000 claims 1
- 108010016731 PPAR gamma Proteins 0.000 claims 1
- 229940080774 Peroxisome proliferator-activated receptor gamma agonist Drugs 0.000 claims 1
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 claims 1
- 229940123934 Reductase inhibitor Drugs 0.000 claims 1
- 102000001494 Sterol O-Acyltransferase Human genes 0.000 claims 1
- 108010054082 Sterol O-acyltransferase Proteins 0.000 claims 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 claims 1
- KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 claims 1
- 229960002632 acarbose Drugs 0.000 claims 1
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 claims 1
- 239000002404 acyltransferase inhibitor Substances 0.000 claims 1
- 239000000048 adrenergic agonist Substances 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 230000036528 appetite Effects 0.000 claims 1
- 235000019789 appetite Nutrition 0.000 claims 1
- 229950010046 avasimibe Drugs 0.000 claims 1
- 150000004283 biguanides Chemical group 0.000 claims 1
- MVCQKIKWYUURMU-UHFFFAOYSA-N cetilistat Chemical compound C1=C(C)C=C2C(=O)OC(OCCCCCCCCCCCCCCCC)=NC2=C1 MVCQKIKWYUURMU-UHFFFAOYSA-N 0.000 claims 1
- 229950002397 cetilistat Drugs 0.000 claims 1
- RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 claims 1
- 239000005516 coenzyme A Substances 0.000 claims 1
- 229940093530 coenzyme a Drugs 0.000 claims 1
- 230000003750 conditioning effect Effects 0.000 claims 1
- 229950006509 dapiclermin Drugs 0.000 claims 1
- KDTSHFARGAKYJN-UHFFFAOYSA-N dephosphocoenzyme A Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 KDTSHFARGAKYJN-UHFFFAOYSA-N 0.000 claims 1
- DLNKOYKMWOXYQA-UHFFFAOYSA-N dl-pseudophenylpropanolamine Natural products CC(N)C(O)C1=CC=CC=C1 DLNKOYKMWOXYQA-UHFFFAOYSA-N 0.000 claims 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 claims 1
- 229960002297 fenofibrate Drugs 0.000 claims 1
- 239000000835 fiber Substances 0.000 claims 1
- 125000001207 fluorophenyl group Chemical group 0.000 claims 1
- 229960003765 fluvastatin Drugs 0.000 claims 1
- 229960004580 glibenclamide Drugs 0.000 claims 1
- 229960000346 gliclazide Drugs 0.000 claims 1
- 229960004346 glimepiride Drugs 0.000 claims 1
- WIGIZIANZCJQQY-RUCARUNLSA-N glimepiride Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)N[C@@H]2CC[C@@H](C)CC2)C=C1 WIGIZIANZCJQQY-RUCARUNLSA-N 0.000 claims 1
- ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 claims 1
- 229960001381 glipizide Drugs 0.000 claims 1
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 claims 1
- 150000002576 ketones Chemical class 0.000 claims 1
- 229960004844 lovastatin Drugs 0.000 claims 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 claims 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 claims 1
- 229960000299 mazindol Drugs 0.000 claims 1
- 229950004994 meglitinide Drugs 0.000 claims 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 claims 1
- PQIOSYKVBBWRRI-UHFFFAOYSA-N methylphosphonyl difluoride Chemical group CP(F)(F)=O PQIOSYKVBBWRRI-UHFFFAOYSA-N 0.000 claims 1
- 108010038232 microsomal triglyceride transfer protein Proteins 0.000 claims 1
- 229960001110 miglitol Drugs 0.000 claims 1
- OELFLUMRDSZNSF-BRWVUGGUSA-N nateglinide Chemical compound C1C[C@@H](C(C)C)CC[C@@H]1C(=O)N[C@@H](C(O)=O)CC1=CC=CC=C1 OELFLUMRDSZNSF-BRWVUGGUSA-N 0.000 claims 1
- 229960000698 nateglinide Drugs 0.000 claims 1
- 229960001243 orlistat Drugs 0.000 claims 1
- 229960003562 phentermine Drugs 0.000 claims 1
- DLNKOYKMWOXYQA-APPZFPTMSA-N phenylpropanolamine Chemical compound C[C@@H](N)[C@H](O)C1=CC=CC=C1 DLNKOYKMWOXYQA-APPZFPTMSA-N 0.000 claims 1
- 229960000395 phenylpropanolamine Drugs 0.000 claims 1
- 229960002965 pravastatin Drugs 0.000 claims 1
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 claims 1
- 229940121649 protein inhibitor Drugs 0.000 claims 1
- 239000012268 protein inhibitor Substances 0.000 claims 1
- 229960002354 repaglinide Drugs 0.000 claims 1
- 229960004586 rosiglitazone Drugs 0.000 claims 1
- 229940076279 serotonin Drugs 0.000 claims 1
- 229960004425 sibutramine Drugs 0.000 claims 1
- UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 claims 1
- 229940031439 squalene Drugs 0.000 claims 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 claims 1
- 229960004394 topiramate Drugs 0.000 claims 1
- GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 claims 1
- 229960001641 troglitazone Drugs 0.000 claims 1
- GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 claims 1
- 229940002552 xenical Drugs 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 4
- 230000003914 insulin secretion Effects 0.000 abstract description 4
- 230000004071 biological effect Effects 0.000 abstract description 3
- 230000004044 response Effects 0.000 abstract description 3
- 101800000224 Glucagon-like peptide 1 Proteins 0.000 abstract description 2
- GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 abstract description 2
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 230000006806 disease prevention Effects 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000002473 insulinotropic effect Effects 0.000 abstract 1
- 230000003278 mimic effect Effects 0.000 abstract 1
- 108091005601 modified peptides Proteins 0.000 abstract 1
- 238000007911 parenteral administration Methods 0.000 abstract 1
- 230000006337 proteolytic cleavage Effects 0.000 abstract 1
- 229940124598 therapeutic candidate Drugs 0.000 abstract 1
- 229920005989 resin Polymers 0.000 description 82
- 239000011347 resin Substances 0.000 description 82
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 51
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 46
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 44
- 239000000243 solution Substances 0.000 description 42
- 230000008878 coupling Effects 0.000 description 36
- 238000010168 coupling process Methods 0.000 description 36
- 238000005859 coupling reaction Methods 0.000 description 36
- 238000002360 preparation method Methods 0.000 description 33
- 235000008729 phenylalanine Nutrition 0.000 description 32
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 29
- 239000000543 intermediate Substances 0.000 description 24
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 23
- 238000006243 chemical reaction Methods 0.000 description 22
- 238000004128 high performance liquid chromatography Methods 0.000 description 22
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 22
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 21
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 20
- DWNBOPVKNPVNQG-LURJTMIESA-N (2s)-4-hydroxy-2-(propylamino)butanoic acid Chemical compound CCCN[C@H](C(O)=O)CCO DWNBOPVKNPVNQG-LURJTMIESA-N 0.000 description 19
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 17
- 239000000203 mixture Substances 0.000 description 17
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 16
- 239000002585 base Substances 0.000 description 15
- 238000005406 washing Methods 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 13
- FPIRBHDGWMWJEP-UHFFFAOYSA-N 1-hydroxy-7-azabenzotriazole Chemical compound C1=CN=C2N(O)N=NC2=C1 FPIRBHDGWMWJEP-UHFFFAOYSA-N 0.000 description 12
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 12
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 11
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 11
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 11
- 239000008103 glucose Substances 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- 230000000875 corresponding effect Effects 0.000 description 10
- 239000007790 solid phase Substances 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical class OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 239000012141 concentrate Substances 0.000 description 9
- 235000008504 concentrate Nutrition 0.000 description 9
- 239000011541 reaction mixture Substances 0.000 description 9
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 8
- 102000035554 Proglucagon Human genes 0.000 description 8
- 108010058003 Proglucagon Proteins 0.000 description 8
- 238000001035 drying Methods 0.000 description 8
- 150000003053 piperidines Chemical class 0.000 description 8
- 229940124530 sulfonamide Drugs 0.000 description 8
- 239000003643 water by type Substances 0.000 description 8
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 235000019439 ethyl acetate Nutrition 0.000 description 7
- 125000001151 peptidyl group Chemical group 0.000 description 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 7
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 7
- KSDTXRUIZMTBNV-INIZCTEOSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)butanedioic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CC(=O)O)C(O)=O)C3=CC=CC=C3C2=C1 KSDTXRUIZMTBNV-INIZCTEOSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 238000005520 cutting process Methods 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 229910052757 nitrogen Inorganic materials 0.000 description 6
- 229920000728 polyester Polymers 0.000 description 6
- 239000000376 reactant Substances 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 6
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 6
- 102000015779 HDL Lipoproteins Human genes 0.000 description 5
- 108010010234 HDL Lipoproteins Proteins 0.000 description 5
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 5
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 5
- 150000001299 aldehydes Chemical class 0.000 description 5
- 150000001721 carbon Chemical group 0.000 description 5
- 238000006482 condensation reaction Methods 0.000 description 5
- 239000012043 crude product Substances 0.000 description 5
- 238000007429 general method Methods 0.000 description 5
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 5
- 239000010410 layer Substances 0.000 description 5
- 238000001819 mass spectrum Methods 0.000 description 5
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 229920006395 saturated elastomer Polymers 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 238000010532 solid phase synthesis reaction Methods 0.000 description 5
- 238000010254 subcutaneous injection Methods 0.000 description 5
- 239000007929 subcutaneous injection Substances 0.000 description 5
- ZGYICYBLPGRURT-UHFFFAOYSA-N tri(propan-2-yl)silicon Chemical compound CC(C)[Si](C(C)C)C(C)C ZGYICYBLPGRURT-UHFFFAOYSA-N 0.000 description 5
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 4
- 101100268670 Caenorhabditis elegans acc-3 gene Proteins 0.000 description 4
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 4
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 4
- 230000006181 N-acylation Effects 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 125000005129 aryl carbonyl group Chemical group 0.000 description 4
- 239000004327 boric acid Substances 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000012044 organic layer Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 238000005932 reductive alkylation reaction Methods 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- 238000010898 silica gel chromatography Methods 0.000 description 4
- 238000004088 simulation Methods 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 230000002194 synthesizing effect Effects 0.000 description 4
- 150000003587 threonine derivatives Chemical class 0.000 description 4
- 238000001291 vacuum drying Methods 0.000 description 4
- JZTKZVJMSCONAK-INIZCTEOSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-hydroxypropanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CO)C(O)=O)C3=CC=CC=C3C2=C1 JZTKZVJMSCONAK-INIZCTEOSA-N 0.000 description 3
- YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 3
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
- 239000004215 Carbon black (E152) Substances 0.000 description 3
- 239000004793 Polystyrene Substances 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 3
- 230000005494 condensation Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 230000037406 food intake Effects 0.000 description 3
- 235000012631 food intake Nutrition 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 125000001188 haloalkyl group Chemical group 0.000 description 3
- 125000005842 heteroatom Chemical group 0.000 description 3
- 229930195733 hydrocarbon Natural products 0.000 description 3
- 150000002430 hydrocarbons Chemical class 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 239000012948 isocyanate Substances 0.000 description 3
- 150000002513 isocyanates Chemical class 0.000 description 3
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 210000000496 pancreas Anatomy 0.000 description 3
- 238000010647 peptide synthesis reaction Methods 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000004007 reversed phase HPLC Methods 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 125000002769 thiazolinyl group Chemical group 0.000 description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 3
- 210000005239 tubule Anatomy 0.000 description 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 3
- QEPWHIXHJNNGLU-KRWDZBQOSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)pentanedioic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CCC(=O)O)C(O)=O)C3=CC=CC=C3C2=C1 QEPWHIXHJNNGLU-KRWDZBQOSA-N 0.000 description 2
- YUGBZNJSGOBFOV-INIZCTEOSA-N (2s)-4-amino-2-(9h-fluoren-9-ylmethoxycarbonylamino)-4-oxobutanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CC(=O)N)C(O)=O)C3=CC=CC=C3C2=C1 YUGBZNJSGOBFOV-INIZCTEOSA-N 0.000 description 2
- IZKGGDFLLNVXNZ-KRWDZBQOSA-N (2s)-5-amino-2-(9h-fluoren-9-ylmethoxycarbonylamino)-5-oxopentanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CCC(=O)N)C(O)=O)C3=CC=CC=C3C2=C1 IZKGGDFLLNVXNZ-KRWDZBQOSA-N 0.000 description 2
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 2
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
- NDKDFTQNXLHCGO-UHFFFAOYSA-N 2-(9h-fluoren-9-ylmethoxycarbonylamino)acetic acid Chemical compound C1=CC=C2C(COC(=O)NCC(=O)O)C3=CC=CC=C3C2=C1 NDKDFTQNXLHCGO-UHFFFAOYSA-N 0.000 description 2
- JDDWRLPTKIOUOF-UHFFFAOYSA-N 9h-fluoren-9-ylmethyl n-[[4-[2-[bis(4-methylphenyl)methylamino]-2-oxoethoxy]phenyl]-(2,4-dimethoxyphenyl)methyl]carbamate Chemical compound COC1=CC(OC)=CC=C1C(C=1C=CC(OCC(=O)NC(C=2C=CC(C)=CC=2)C=2C=CC(C)=CC=2)=CC=1)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 JDDWRLPTKIOUOF-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 2
- 239000005695 Ammonium acetate Substances 0.000 description 2
- CKDWPUIZGOQOOM-UHFFFAOYSA-N Carbamyl chloride Chemical compound NC(Cl)=O CKDWPUIZGOQOOM-UHFFFAOYSA-N 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 2
- 102400000326 Glucagon-like peptide 2 Human genes 0.000 description 2
- 101800000221 Glucagon-like peptide 2 Proteins 0.000 description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- LSDPWZHWYPCBBB-UHFFFAOYSA-N Methanethiol Chemical compound SC LSDPWZHWYPCBBB-UHFFFAOYSA-N 0.000 description 2
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 2
- 238000006069 Suzuki reaction reaction Methods 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 150000008065 acid anhydrides Chemical class 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 2
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 description 2
- 125000003282 alkyl amino group Chemical group 0.000 description 2
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 description 2
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 2
- 235000019257 ammonium acetate Nutrition 0.000 description 2
- 229940043376 ammonium acetate Drugs 0.000 description 2
- 125000004659 aryl alkyl thio group Chemical group 0.000 description 2
- 125000005100 aryl amino carbonyl group Chemical group 0.000 description 2
- 125000005135 aryl sulfinyl group Chemical group 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 229960000846 camphor Drugs 0.000 description 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 150000001805 chlorine compounds Chemical class 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- OMFXVFTZEKFJBZ-HJTSIMOOSA-N corticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OMFXVFTZEKFJBZ-HJTSIMOOSA-N 0.000 description 2
- 238000013016 damping Methods 0.000 description 2
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N formaldehyde Natural products O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- TWSALRJGPBVBQU-PKQQPRCHSA-N glucagon-like peptide 2 Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O)[C@@H](C)CC)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=CC=C1 TWSALRJGPBVBQU-PKQQPRCHSA-N 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- NQIFXJSLCUJHBB-LBPRGKRZSA-N methyl (2s)-3-(4-hydroxyphenyl)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoate Chemical class CC(C)(C)OC(=O)N[C@H](C(=O)OC)CC1=CC=C(O)C=C1 NQIFXJSLCUJHBB-LBPRGKRZSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N mono-methylamine Natural products NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 238000000643 oven drying Methods 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 229920005990 polystyrene resin Polymers 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 239000012266 salt solution Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000036186 satiety Effects 0.000 description 2
- 235000019627 satiety Nutrition 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 description 2
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- WTFNSXYULBQCQV-UHFFFAOYSA-N $l^{1}-oxidanyloxymethane Chemical group CO[O] WTFNSXYULBQCQV-UHFFFAOYSA-N 0.000 description 1
- HTGQCLJTWPSFNL-UHFFFAOYSA-N (2-methylphenoxy)boronic acid Chemical compound CC1=CC=CC=C1OB(O)O HTGQCLJTWPSFNL-UHFFFAOYSA-N 0.000 description 1
- OBDTYOCDTWYTGV-YFKPBYRVSA-N (2r)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-3-sulfopropanoic acid Chemical compound CC(C)(C)OC(=O)N[C@H](C(O)=O)CS(O)(=O)=O OBDTYOCDTWYTGV-YFKPBYRVSA-N 0.000 description 1
- SWZCTMTWRHEBIN-QFIPXVFZSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-(4-hydroxyphenyl)propanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)C1=CC=C(O)C=C1 SWZCTMTWRHEBIN-QFIPXVFZSA-N 0.000 description 1
- SJVFAHZPLIXNDH-QFIPXVFZSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-phenylpropanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)C1=CC=CC=C1 SJVFAHZPLIXNDH-QFIPXVFZSA-N 0.000 description 1
- CBPJQFCAFFNICX-IBGZPJMESA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-4-methylpentanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CC(C)C)C(O)=O)C3=CC=CC=C3C2=C1 CBPJQFCAFFNICX-IBGZPJMESA-N 0.000 description 1
- VCFCFPNRQDANPN-IBGZPJMESA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)hexanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CCCC)C(O)=O)C3=CC=CC=C3C2=C1 VCFCFPNRQDANPN-IBGZPJMESA-N 0.000 description 1
- QWXZOFZKSQXPDC-NSHDSACASA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)propanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](C)C(O)=O)C3=CC=CC=C3C2=C1 QWXZOFZKSQXPDC-NSHDSACASA-N 0.000 description 1
- PAAZPARNPHGIKF-UHFFFAOYSA-N 1,2-dibromoethane Chemical compound BrCCBr PAAZPARNPHGIKF-UHFFFAOYSA-N 0.000 description 1
- OTEKOJQFKOIXMU-UHFFFAOYSA-N 1,4-bis(trichloromethyl)benzene Chemical compound ClC(Cl)(Cl)C1=CC=C(C(Cl)(Cl)Cl)C=C1 OTEKOJQFKOIXMU-UHFFFAOYSA-N 0.000 description 1
- HVRUGFJYCAFAAN-UHFFFAOYSA-N 1-bromo-2-ethylbenzene Chemical class CCC1=CC=CC=C1Br HVRUGFJYCAFAAN-UHFFFAOYSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- XXMFJKNOJSDQBM-UHFFFAOYSA-N 2,2,2-trifluoroacetic acid;hydrate Chemical compound [OH3+].[O-]C(=O)C(F)(F)F XXMFJKNOJSDQBM-UHFFFAOYSA-N 0.000 description 1
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-Lutidine Substances CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 1
- CPHXLFKIUVVIOQ-UHFFFAOYSA-N 2-(trifluoromethoxy)benzaldehyde Chemical group FC(F)(F)OC1=CC=CC=C1C=O CPHXLFKIUVVIOQ-UHFFFAOYSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- WTOFYLAWDLQMBZ-UHFFFAOYSA-N 2-azaniumyl-3-thiophen-2-ylpropanoate Chemical compound OC(=O)C(N)CC1=CC=CS1 WTOFYLAWDLQMBZ-UHFFFAOYSA-N 0.000 description 1
- 125000004777 2-fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 description 1
- NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical compound C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 1
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 1
- YNQLUTRBYVCPMQ-UHFFFAOYSA-N Ethylbenzene Chemical compound CCC1=CC=CC=C1 YNQLUTRBYVCPMQ-UHFFFAOYSA-N 0.000 description 1
- 102400000322 Glucagon-like peptide 1 Human genes 0.000 description 1
- 101800004295 Glucagon-like peptide 1(7-36) Proteins 0.000 description 1
- 101800004266 Glucagon-like peptide 1(7-37) Proteins 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- QMXOFBXZEKTJIK-UHFFFAOYSA-N Glycinol Natural products C1=C(O)C=C2OCC3(O)C4=CC=C(O)C=C4OC3C2=C1 QMXOFBXZEKTJIK-UHFFFAOYSA-N 0.000 description 1
- 229910004373 HOAc Inorganic materials 0.000 description 1
- 101000886868 Homo sapiens Gastric inhibitory polypeptide Proteins 0.000 description 1
- 229910010082 LiAlH Inorganic materials 0.000 description 1
- 239000012448 Lithium borohydride Substances 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- KAFHLONDOVSENM-HNNXBMFYSA-N O-Benzyl-L-tyrosine Chemical compound C1=CC(C[C@H](N)C(O)=O)=CC=C1OCC1=CC=CC=C1 KAFHLONDOVSENM-HNNXBMFYSA-N 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- 102100041030 Pancreas/duodenum homeobox protein 1 Human genes 0.000 description 1
- 101710144033 Pancreas/duodenum homeobox protein 1 Proteins 0.000 description 1
- 102100040918 Pro-glucagon Human genes 0.000 description 1
- WUGQZFFCHPXWKQ-UHFFFAOYSA-N Propanolamine Chemical compound NCCCO WUGQZFFCHPXWKQ-UHFFFAOYSA-N 0.000 description 1
- BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 235000013832 Valeriana officinalis Nutrition 0.000 description 1
- 244000126014 Valeriana officinalis Species 0.000 description 1
- UOHUDFHWFDUDID-UHFFFAOYSA-N [Cl].C[SiH](C)C Chemical compound [Cl].C[SiH](C)C UOHUDFHWFDUDID-UHFFFAOYSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000005224 alkoxybenzenes Chemical class 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 150000004982 aromatic amines Chemical group 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 150000003851 azoles Chemical class 0.000 description 1
- YAVVGPBYBUYPSR-UHFFFAOYSA-N benzene;oxygen Chemical compound [O].C1=CC=CC=C1 YAVVGPBYBUYPSR-UHFFFAOYSA-N 0.000 description 1
- QRUDEWIWKLJBPS-UHFFFAOYSA-N benzotriazole Chemical compound C1=CC=C2N[N][N]C2=C1 QRUDEWIWKLJBPS-UHFFFAOYSA-N 0.000 description 1
- 239000012964 benzotriazole Substances 0.000 description 1
- 230000003570 biosynthesizing effect Effects 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- ACBQROXDOHKANW-UHFFFAOYSA-N bis(4-nitrophenyl) carbonate Chemical compound C1=CC([N+](=O)[O-])=CC=C1OC(=O)OC1=CC=C([N+]([O-])=O)C=C1 ACBQROXDOHKANW-UHFFFAOYSA-N 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 125000005112 cycloalkylalkoxy group Chemical group 0.000 description 1
- 125000005167 cycloalkylaminocarbonyl group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000007872 degassing Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 239000012259 ether extract Substances 0.000 description 1
- 238000003810 ethyl acetate extraction Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 125000005519 fluorenylmethyloxycarbonyl group Chemical group 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 150000002240 furans Chemical class 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 239000003629 gastrointestinal hormone Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000014101 glucose homeostasis Effects 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- JMANVNJQNLATNU-UHFFFAOYSA-N glycolonitrile Natural products N#CC#N JMANVNJQNLATNU-UHFFFAOYSA-N 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004447 heteroarylalkenyl group Chemical group 0.000 description 1
- 125000005241 heteroarylamino group Chemical group 0.000 description 1
- 125000005222 heteroarylaminocarbonyl group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- DWKPPFQULDPWHX-VKHMYHEASA-N l-alanyl ester Chemical compound COC(=O)[C@H](C)N DWKPPFQULDPWHX-VKHMYHEASA-N 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000037323 metabolic rate Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 1
- YPJKMVATUPSWOH-UHFFFAOYSA-N nitrooxidanyl Chemical compound [O][N+]([O-])=O YPJKMVATUPSWOH-UHFFFAOYSA-N 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 1
- MUMZUERVLWJKNR-UHFFFAOYSA-N oxoplatinum Chemical compound [Pt]=O MUMZUERVLWJKNR-UHFFFAOYSA-N 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- GJSGGHOYGKMUPT-UHFFFAOYSA-N phenoxathiine Chemical compound C1=CC=C2OC3=CC=CC=C3SC2=C1 GJSGGHOYGKMUPT-UHFFFAOYSA-N 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- QIIPQYDSKRYMFG-UHFFFAOYSA-N phenyl hydrogen carbonate Chemical compound OC(=O)OC1=CC=CC=C1 QIIPQYDSKRYMFG-UHFFFAOYSA-N 0.000 description 1
- 150000002993 phenylalanine derivatives Chemical class 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- XUWHAWMETYGRKB-UHFFFAOYSA-N piperidin-2-one Chemical compound O=C1CCCCN1 XUWHAWMETYGRKB-UHFFFAOYSA-N 0.000 description 1
- 125000005936 piperidyl group Chemical group 0.000 description 1
- 229910003446 platinum oxide Inorganic materials 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000002952 polymeric resin Substances 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 1
- 235000015320 potassium carbonate Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 201000009104 prediabetes syndrome Diseases 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 1
- 150000003222 pyridines Chemical class 0.000 description 1
- 150000003233 pyrroles Chemical class 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000009991 scouring Methods 0.000 description 1
- 229910000077 silane Inorganic materials 0.000 description 1
- 238000010129 solution processing Methods 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 229920003002 synthetic resin Polymers 0.000 description 1
- VPSCDCAALIWDMO-UHFFFAOYSA-N tert-butyl 2-(2-methylphenyl)benzoate Chemical compound CC1=CC=CC=C1C1=CC=CC=C1C(=O)OC(C)(C)C VPSCDCAALIWDMO-UHFFFAOYSA-N 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 125000005958 tetrahydrothienyl group Chemical group 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- AJSTXXYNEIHPMD-UHFFFAOYSA-N triethyl borate Chemical compound CCOB(OCC)OCC AJSTXXYNEIHPMD-UHFFFAOYSA-N 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- FTVLMFQEYACZNP-UHFFFAOYSA-N trimethylsilyl trifluoromethanesulfonate Chemical compound C[Si](C)(C)OS(=O)(=O)C(F)(F)F FTVLMFQEYACZNP-UHFFFAOYSA-N 0.000 description 1
- 150000003667 tyrosine derivatives Chemical class 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
- 238000002211 ultraviolet spectrum Methods 0.000 description 1
- 125000002948 undecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000016788 valerian Nutrition 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Ophthalmology & Optometry (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
化合物# | Xaa1 Xaa2 Xaa3 | Xaa4 Xaa5 Xaa6 | Xaa7 Xaa8 Xaa9 | Y | Z |
1 | H A E | G T F | T S D | Bip | Phe(4-NO2) |
2 | H A E | G T F | T S D | Bip | 2-Nal |
3 | H A E | G T F | T S D | Bip | Bip |
4 | H A E | G T F | T S D | Bip | Phe(五氟) |
5 | H A E | G T F | T S D | Bip | Phe(4-甲基) |
6 | H A E | G T F | T S D | 2-Nal | Bip |
7 | H A E | G T F | T S D | Bip | F |
8 | H A E | G T F | T S D | Bip | Y |
9 | H A E | G T F | T S D | 2-Nal | Phe(五氟) |
10 | H A E | G T F | T S D | Bip | Phe(4-碘) |
11 | H A E | G T F | T S D | Bip(2-甲基) | Bip(4-氧甲基) |
12 | H A E | G T F | T S D | Bip(2-甲基) | Bip(3,4-亚甲基二氧基) |
13 | H A E | G T F | T S D | Bip(2-甲基) | 4-(1-萘基)-Phe |
14 | H A E | G T F | T S D | Bip(2-甲基) | Bip(4-甲基) |
15 | H A E | G T F | T S D | Bip(2-甲基) | Bip(3-甲基) |
16 | H A E | G T F | T S D | Bip(2,4-二氧甲基 | Bip(2-甲基) |
17 | H A E | G T F | T S D | Bip(2-甲基,4-氧甲基) | Bip(2-甲基) |
18 | H A D | G T F | T S D | Bip(2-甲基) | Bip(2-甲基) |
19 | H A E | G Nle F | T S D | Bip(2-甲基) | Bip(2-甲基) |
20 | H A E | G T Phe(五氟) | T S D | Bip(2-甲基) | Bip(2-甲基) |
21 | H A H | G T Phe(五氟) | T S D | Bip(2-甲基) | Bip(2-甲基) |
22 | H A D | G Nle F | T S D | Bip(2-甲基) | Bip(2-甲基) |
23 | H A E | G Nle Phe(五氟) | T S D | Bip(2-甲基) | Bip(2-甲基) |
24 | H A E | G Nle F | T H D | Bip(2-甲基) | Bip(2-甲基) |
25 | H ala D | G Nle F | T S D | Bip(2-甲基) | Bip(2-甲基) |
26 | H ala D | G T Phe(五氟) | T S D | Bip(2-甲基) | Bip(2-甲基) |
27 | H A H | G Nle Phe(五氟) | T S D | Bip(2-甲基) | Bip(2-甲基) |
28 | H A H | G T Phe(五氟) | T H D | Bip(2-甲基) | Bip(2-甲基) |
29 | H A D | G T Phe(五氟) | T H D | Bip(2-甲基) | Bip(2-甲基) |
30 | H A D | G Nle F | T H D | Bip(2-甲基) | Bip(2-甲基) |
31 | H ala D | G Nle Phe(五氟) | T S D | Bip(2-甲基) | Bip(2-甲基) |
32 | H A E | G T F | T S D | Bip(2-乙基) | Bip |
33 | H A E | G Nle Phe(五氟) | T H D | Bip(2-甲基) | Bip(2-甲基) |
34 | H A E | G T F | T S D | Bip(2-氧乙基) | Bip(2-甲基) |
35 | H A E | G T F | T S D | Bip(2-丙基) | Bip(2-甲基) |
36 | H A E | G T F | T S D | Bip(2-丙基,4-氧甲基) | Bip(2-甲基) |
37 | H A E | G T F | T S D | Bip(2-三氟甲基) | Bip |
38 | H A E | G T F | T S D | Bip(2-氯) | Bip |
39 | H A E | G T F | T S D | Bip(2-氟) | Bip |
40 | H A E | G T F | T S D | Bip(4-三氟甲基) | Bip |
41 | H A E | G T F | T S D | 4-(1-萘基)-Phe | Bip |
42 | H A E | G T F | T S D | 4-(3-噻吩)-Phe | Bip |
43 | H A E | G T F | T S D | 4-(3-喹啉)-Phe | Bip |
44 | H A E | G T F | T S D | Bip(2-甲基) | Phe(五氟) |
45 | H A E | G T F | T S D | Bip(2-氧甲基) | Phe(五氟) |
46 | H A E | G T F | T S D | Bip(2-三氟甲基) | Phe(五氟) |
47 | H A E | G T F | T S D | Bip(2-三氟甲基) | Phe(五氟) |
48 | H A E | G T F | T S D | Bip(2-氯) | Phe(五氟) |
49 | H A E | G T F | T S D | Bip(2-氟) | Phe(五氟) |
50 | H A E | G T F | T S D | Bip(4-氧甲基) | Phe(五氟) |
51 | H A E | G T F | T S D | Bip(3,4-亚甲基二氧基) | Phe(五氟) |
52 | H A E | G T F | T S D | Bip(2-甲基) | 2-Nal |
53 | H A E | G T F | T S D | Bip(2-氧甲基) | 2-Nal |
54 | H A E | G T F | T S D | Bip(2-三氟甲基) | 2-Nal |
55 | H A E | G T F | T S D | Bip(2-氯) | 2-Nal |
56 | H A E | G T F | T S D | Bip(2-氟) | 2-Nal |
57 | H A E | G T F | T S D | Bip(4-甲基) | 2-Nal |
58 | H A E | G T F | T S D | Bip(4-氧甲基) | 2-Nal |
59 | H A E | G T F | T S D | Bip(3,4-亚甲基二氧基) | 2-Nal |
60 | H A E | G T F | T S D | 4-(1-萘基)-Phe | 2-Nal |
61 | H A E | G T F | T S D | 4-(3-噻吩)-Phe | 2-Nal |
62 | H A E | G T F | T S D | Bip(2-甲基) | Phe(4-甲基) |
63 | H A E | G T F | T S D | Bip(2-三氟甲基) | Phe(4-甲基) |
64 | H A E | G T F | T S D | Bip(2-氯) | Phe(4-甲基) |
65 | H A E | G T F | T S D | Bip(2-氟) | Phe(4-甲基) |
66 | H A E | G T F | T S D | Bip(4-氯) | Phe(4-甲基) |
67 | H A E | G T F | T S D | Bip(4-甲基) | Phe(4-甲基) |
68 | H A E | G T F | T S D | Bip(4-氟) | Phe(4-甲基) |
69 | H A E | G T F | T S D | Bip(4-氧甲基) | Phe(4-甲基) |
70 | H A E | G T F | T S D | Bip(3,4-亚甲基二氧) | Phe(4-甲基) |
71 | H A E | G T F | T S D | 4-(1-萘基)-Phe | Phe(4-甲基) |
72 | H A E | G T F | T S D | Bip(3-苯基) | Phe(4-甲基) |
73 | H A E | G T F | T S D | Bip(2-甲基) | Bip(2-氟) |
74 | H A E | G T F | T S D | Bip(2-甲基) | Bip(4-苯基) |
75 | H A E | G T F | T S D | Bip(2-甲基) | Bip(3-氧甲基) |
76 | H A E | G T F | T S D | Bip(2-甲基) | 4-(3-吡啶基)-Phe |
77 | H A E | G T F | T S D | Phe(五氟) | Bip(4-氧甲基) |
78 | H A E | G T F | T S D | Bip(2-甲基) | Bip(3-乙酰氨基) |
79 | H A E | G T F | T S D | Bip(2-甲基) | Bip(4-异丙基) |
80 | H A E | G T F | T S D | Bip | 4-(1-萘基)-Phe |
81 | H A E | G T F | T S D | Bip | 4-(3-吡啶基)-Phe |
82 | H A E | G T F | T S D | Phe(五氟) | Bip(2-甲基) |
83 | H A E | G T F | T S D | 2-Nal | Bip(2-甲基) |
84 | H A E | G T F | T S D | Phe(4-碘) | Bip(2-甲基) |
85 | H A E | G T F | T S D | Phe(3,4-二-氯) | Bip(2-甲基) |
86 | H A E | G T F | T S D | Tyr(Bzl) | Bip(2-甲基) |
87 | H A E | G T F | T S D | HomoPhe | Bip(2-甲基) |
88 | H A E | G T F | T S D | Bip(2,4-二-氧甲基) | Bip |
89 | H A E | G T F | T S D | 4-(4-(3,5-二甲基异噁唑))-Phe | Bip |
90 | H A E | G T F | T S D | Bip(2-甲基,4-氧甲基) | Bip |
91 | H A E | G T F | T S D | Bip(2,6-二甲基) | Bip |
92 | H A E | G T F | T S D | Bip(2,4-二甲基) | Bip |
93 | H A E | G T F | T S D | Bip(2,3-二甲基) | Bip |
94 | H A E | G T F | T S D | Bip(4-三氟甲氧基) | Bip |
95 | H A E | G T F | T S D | Bip(4-乙基) | Bip |
96 | H A E | G T F | T S D | 4-(2-萘基)-Phe | Bip |
97 | H A E | G T F | T S D | 4-(4-二苯并呋喃)-Phe | Bip |
98 | H A E | G T F | T S D | Bip(2,6-二-氧甲基) | Bip(2-甲基) |
99 | H A E | G T F | T S D | 4-(2,4-二甲氧嘧啶)-Phe | Bip(2-甲基) |
100 | H A E | G T F | T S D | Bip(2,4,6-三甲基) | Bip(2-甲基) |
101 | H A E | G T F | T S D | 4-(4-(3,5-二甲基异噁唑))-Phe | Bip(2-甲基) |
102 | H A E | G T F | T S D | Bip(2,4-二氯) | Bip(2-甲基) |
103 | H A E | G T F | T S D | Bip(2,6-二甲基) | Bip(2-甲基) |
104 | H A E | G T F | T S D | Bip(2,4-二甲基) | Bip(2-甲基) |
105 | H A E | G T F | T S D | Bip(2,3-二甲基) | Bip(2-甲基) |
106 | H A E | G T F | T S D | Bip(4-乙基) | Bip(2-甲基) |
107 | H A E | G T F | T S D | Bip(4-硫甲基) | Bip(2-甲基) |
108 | H A E | G T F | T S D | Bip(4-氧乙基) | Bip(2-甲基) |
109 | H A E | G T F | T S D | 4-(2-萘基)-Phe | Bip(2-甲基) |
110 | H A E | G T F | T S D | 4-(2-苯并(b)噻吩)-Phe | Bip(2-甲基) |
111 | H A E | G T F | T S D | 4-(2-苯并(b)呋 | Bip(2-甲基) |
喃)-Phe | |||||
112 | H A E | G T F | T S D | 4-(4-二苯并呋喃)-Phe | Bip(2-甲基) |
113 | H A E | G T F | T S D | 4-(4-酚黄素)-Phe | Bip(2-甲基) |
114 | H A E | G T F | T S D | Bip(2-甲基) | Bip(4-乙基) |
115 | H A E | G T F | T S D | Bip(2-甲基) | Bip(4-硫甲基) |
116 | H A E | G T F | T S D | Bip(2-甲基) | Bip(2,4-二甲基) |
117 | H A E | G T F | T S D | Bip(2-甲基) | Bip(2-甲基,4-氧甲基) |
118 | H A E | G T F | T S D | Bip(2-甲基) | Bip(2,3-二甲基) |
119 | H A E | G T F | T S D | Bip(2-甲基) | 4-(2-萘基)-Phe |
120 | H A E | G T F | T S D | Bip(2-甲基) | Bip(2-氧乙基) |
121 | H A E | G T F | T S D | Bip(2-甲基) | Bip(2-乙基,4-氧甲基) |
122 | H A E | G T F | T S D | Bip(2-乙基) | Bip(3-乙基) |
123 | H A E | G T F | T S D | Bip(2-乙基) | Bip(3-丙基) |
124 | H A E | G T F | T S D | Bip(2-乙基) | Bip(3-苯基) |
125 | H A E | G T F | T S D | Bip(2-乙基) | Bip(3-氧乙基) |
126 | H A E | G T F | T S D | Bip(2-乙基) | Bip(4-乙基) |
127 | H A E | G T F | T S D | Bip(2-乙基) | Bip(4-硫甲基) |
128 | H A E | G T F | T S D | Bip(2-乙基) | Bip(4-OCF3) |
129 | H A E | G T F | T S D | Bip(2-乙基) | Bip(4-氧乙基) |
130 | H A E | G T F | T S D | Bip(2-乙基) | Bip(2-甲基,4-氧甲基) |
131 | H A E | G T F | T S D | Bip(2-乙基) | Bip(2,6-二甲基) |
132 | H A E | G T F | T S D | Bip(2-乙基) | Bip(2,4,6-三甲基) |
133 | H A E | G T F | T S D | Bip(2-乙基) | Bip(2-苯基) |
134 | H A E | G T F | T S D | Bip(2-乙基) | Bip(2-异丙基) |
135 | H A E | G T F | T S D | Bip(2-乙基) | 4-(2-萘基)-Phe |
136 | H A E | G T F | T S D | Bip(2-乙基) | Bip(2,5-二-氧甲基) |
137 | H A E | G T F | T S D | Bip(2-乙基) | Bip(2-氧乙基) |
138 | H A E | G T F | T S D | Bip(2-乙基) | Bip(3,4-二-氧甲基) |
139 | H A E | G T F | T S D | Bip(2-乙基) | Bip(2-乙基,4-氧甲基) |
140 | H ala E | G Nle Phe(五氟) | T S D | Bip(2-甲基) | Bip(2-甲基) |
141 | H A H | G T F | T H D | Bip(2-甲基) | Bip(2-甲基) |
142 | H A H | G T F | T S D | Bip(2-甲基) | Bip(2-甲基) |
143 | H A E | G T F | T S D | Bip | Phe(4-三氟甲基) |
144 | H Aib E | G Nle Phe(五氟) | T S D | Bip(2-乙基) | Bip(2-甲基) |
145 | H Aib D | G T F | T S D | Bip(2-乙基) | Bip(2-甲基) |
146 | H Aib D | G Nle F | T H D | Bip(2-乙基) | Bip(2-甲基) |
147 | H Aib H | G T Phe(五氟) | T H D | Bip(2-乙基) | Bip(2-甲基) |
148 | H Aib D | G Nle F | T S D | Bip(2-乙基) | Bip(2-甲基) |
149 | H Aib H | G T F | T H D | Bip(2-乙基) | Bip(2-甲基) |
150 | H ala asp | G Nle Phe(五氟) | T S D | Bip(2-甲基) | Bip(2-甲基) |
151 | H A D | G Nle F | T H D | Bip(2-乙基) | Bip(2-甲基) |
152 | H ala D | G Nle Phe(五氟) | T H D | Bip(2-乙基) | Bip(2-甲基) |
153 | H A D | G T (L)-Phe(2,4-二氟) | T S D | Bip(2-甲基) | Bip(2-甲基) |
154 | H Aib asp | G Nle Phe(五氟) | T S D | Bip(2-甲基) | Bip(2-甲基) |
155 | H A D | G T (D)-Phe(2,4-二氟) | T S D | Bip(2-甲基) | Bip(2-甲基) |
156 | H Aib D | G Nle F | T H D | Bip(2-甲基) | Bip(2-甲基) |
157 | H Aib D | G Nle F | T S D | Bip(2-甲基) | Bip(2-甲基) |
158 | H Aib D | G T F | T S D | Bip(2-甲基) | Bip(2-甲基) |
159 | H Aib D | G T Phe(五氟) | T S D | Bip(2-甲基) | Bip(2-甲基) |
160 | H Aib E | G Nle F | T S D | Bip(2-甲基) | Bip(2-甲基) |
161 | H Aib E | G Nle Phe(五氟) | T H D | Bip(2-甲基) | Bip(2-甲基) |
162 | H Aib E | G Nle Phe(五氟) | T S D | Bip(2-甲基) | Bip(2-甲基) |
163 | H Aib E | G T Phe(五氟) | T H D | Bip(2-甲基) | Bip(2-甲基) |
164 | H Aib E | G T Phe(五氟) | T S D | Bip(2-甲基) | Bip(2-甲基) |
165 | H Aib H | G T F | T H D | Bip(2-甲基) | Bip(2-甲基) |
166 | H Aib H | G T F | T S D | Bip(2-甲基) | Bip(2-甲基) |
167 | H Aib H | G T Phe(五氟) | T H D | Bip(2-甲基) | Bip(2-甲基) |
168 | his Aib D | G Nle Phe(五氟) | T S D | Bip(2-甲基) | Bip(2-甲基) |
169 | H ala D | G Nle Phe(五氟) | T S D | Bip(2-乙基) | Bip(2-甲基) |
170 | H Aib D | G Nle Phe(五氟) | T S D | Bip(2-乙基) | Bip(2-甲基) |
171 | H Aib D | G Nle Phe(五氟) | T S D | Bip(2-甲基) | Bip(2-乙基) |
172 | H Aib D | G Nle Phe(五氟) | T S D | Phe(五氟) | Bip(2-甲基) |
173 | H ala D | G T Phe(五氟) | T S D | Bip(2-乙基) | Bip(2-甲基) |
174 | H Aib E | G T Phe(五氟) | T S D | Bip(2-乙基) | Bip(2-甲基) |
175 | H A D | G T (L)-Phe(2,5-二-F) | T S D | Bip(2-甲基) | Bip(2-甲基) |
176 | H A Dpr | G T Phe(五氟) | T S D | Bip(2-乙基) | Bip(2-甲基) |
177 | H Aib Dpr | G T Phe(五氟) | T S D | Bip(2-乙基) | Bip(2-甲基) |
178 | H ala Dpr | G Nle Phe(五氟) | T S D | Bip(2-乙基,2’-甲基) | Bip(2-甲基) |
179 | H A Dpr | G T Phe(五氟) | T S D | Bip(2-乙基,2’-甲基) | Bip(2-甲基) |
180 | H A Dpr | G T F | T S D | Bip(2-乙基,2’-甲基) | Bip(2-甲基) |
181 | H lva E | G T F | T S D | Bip(2-甲基) | Bip(2-甲基) |
182 | H A E | G homo FLeu | T S D | Bip(2-甲基) | Bip(2-甲基) |
183 | H A E | G T homoLeu | T S D | Bip(2-甲基) | Bip(2-甲基) |
184 | H A E | G T F | T S D | 2-(9,10-二氢菲基)-Ala | Bip(2-甲基) |
185 | H A E | G T F | T S D | Bip(2-乙基) | 2-(9,10-二氢菲基)-A1a |
186 | H A E | G T F | T S D | Bip(2-乙基) | 2-(9,10-二氢菲基)-Ala |
187 | H A E | G T F | T S D | 2-(9,10-二氢菲基)-Ala | 2-(9,10-二氢菲基)-Ala |
188 | H A E | G T F | T S D | 2-(9,10-二氢菲基)-Ala | 2-(9,10-二氢菲基)-Ala |
189 | H A E | G T F | T S D | 2-芴基Ala | 2-(9,10-二氢菲基)-Ala |
190 | H A E | G T F | T S D | 2-(9,10-二氢菲基)-Ala | 2-芴基Ala |
191 | H A E | G T F | T S D | 2-(9,10-二氢菲基)-Ala | 2-芴基Ala |
192 | H A E | G T F | T S D | Bip(2-乙基,2’-乙基) | Bip |
193 | H A E | G T F | T S D | Bip(2-乙基,2’-乙基) | Bip(2-甲基) |
194 | H ala D | G Nle Phe(五氟) | T S D | Bip(2-乙基,4-氧甲基) | Bip(2-甲基) |
195 | H A E | G T F | T S D | Bip(2-丙基,2’-甲基) | Bip |
196 | H A D | G T L-α-甲基-Phe | T S D | Bip | Bip(2-乙基) |
197 | H A D | G T L-α-甲基 | T S D | Bip(2-乙基) | Bip(2-乙基) |
-Phe | |||||
198 | H A D | G T L-α-甲基-Phe | T S D | Bip(2-甲基) | Bip(2-乙基) |
199 | H ala E | G T L-α-甲基-Phe | T S D | Bip(2-乙基) | Bip(2-甲基) |
200 | H A D | G T L-α-甲基-Phe | T S D | Bip | Bip |
201 | H ala asp | G Nle L-α-甲基-Phe | T S D | Bip(2-甲基) | Bip(2-甲基) |
202 | H ala D | G Nle L-α-甲基-Phe | T S D | Bip(2-甲基) | Bip(2-甲基) |
203 | H Aib D | G Nle L-α-甲基-Phe | T S D | Bip(2-甲基) | Bip(2-甲基) |
204 | H Aib D | G Nle L-α-甲基-Phe | thr S D | Bip(2-甲基) | Bip(2-甲基) |
205 | H Aib D | G Nle L-α-甲基-Phe | T ser D | Bip(2-甲基) | Bip(2-甲基) |
206 | H Aib D | G Nle L-α-甲基-Phe | T S D | Bip(2-甲基) | Bip |
207 | H G E | G T F | T S D | Bip(2-甲基) | Bip(2-甲基) |
208 | H A E | G T F | T S D | Bip(2-乙基,4-氧甲基) | Bip(2,4-二-甲基) |
209 | H A E | G T F | T S D | Bip(2-乙基,4-氧甲基) | Bip(4-氧甲基) |
210 | H A E | G T F | T S D | Bip(2-乙基,4-氧甲基) | Bip(3-甲基) |
211 | H A E | G T F | T S D | Bip(2-CH2OH,4-氧甲基) | Bip(2-甲基) |
212 | H A E | G T F | T S D | Bip(2-甲基) | Bip(2-丙基,2’-甲基) |
213 | H A E | G T F | T S D | Bip(2-乙基,4-氧甲基) | Bip(2,3,4,5-四甲基) |
214 | H A E | G T F | T S D | Bip(2-乙基) | Bip(2,2’-二甲基) |
215 | H A D | G T Phe(2-氧甲基) | T S D | Bip(2-甲基) | Bip(2-甲基) |
216 | H A D | G T Phe(2-羟基) | T S D | Bip(2-甲基) | Bip(2-甲基) |
217 | H A D | G T Phe(2-碘) | T S D | Bip(2-甲基) | Bip(2-甲基) |
218 | H A D | G T Phe(3-氧甲基) | T S D | Bip(2-甲基) | Bip(2-甲基) |
219 | H A D | G T Tyr(3-碘) | T S D | Bip(2-甲基) | Bip(2-甲基) |
220 | H A D | G T Tyr(3-NO2) | T S D | Bip(2-甲基) | Bip(2-甲基) |
221 | H A D | G T (L)-Phe(2,3-二氟) | T S D | Bip(2-甲基) | Bip(2-甲基) |
222 | H A D | G T Tyr(2,6-二甲基) | T S D | Bip(2-甲基) | Bip(2-甲基) |
223 | H A D | G T 2-噻吩基丙氨酸 | T S D | Bip(2-甲基) | Bip(2-甲基) |
224 | H A D | G T (D)-Phe(2,3-二氟) | T S D | Bip(2-甲基) | Bip(2-甲基) |
225 | H A E | G T F | T S D | Bip(2-乙基,2’-甲基) | Bip(2-乙基) |
226 | H ala D | G Nle F | T S D | Bip(2-乙基,2’-甲基) | Bip(2-甲基) |
227 | H Acc3 D | G Nle Phe(五氟) | T S D | Bip(2-甲基) | Bip(2-甲基) |
228 | H Acc3 D | G Nle F | T H D | Bip(2-甲基) | Bip(2-甲基) |
229 | H Acc3 D | G T Phe(五氟) | T H D | Bip(2-甲基) | Bip(2-甲基) |
230 | H Acc3 D | G Nle Phe(五氟) | T H D | Bip(2-甲基) | Bip(2-甲基) |
231 | H A D | G T Phe(2-三氟甲基) | T S D | Bip(2-甲基) | Bip(2-甲基) |
232 | H A D | G T Phe(2,4-二氯) | T S D | Bip(2-甲基) | Bip(2-甲基) |
233 | H 2-Abu E | G T F | T S D | Bip(2-甲基) | Bip(2-甲基) |
234 | his A asp | G Nle Phe(五氟) | T S D | Bip(2-甲基) | Bip(2-甲基) |
235 | H A E | G Nle Phe(五氟) | T H D | Bip(2-乙基) | Bip(2-甲基) |
236 | H Aib D | G T Phe(五氟) | T S D | Bip(2-乙基) | Bip(2-甲基) |
237 | H Aib E | G Nle Phe(五氟) | T H D | Bip(2-乙基) | Bip(2-甲基) |
238 | H A E | G T Phe(2-甲基) | T S D | Bip(2-甲基) | Bip(2-甲基) |
239 | H A E | G T F | T S D | Bip(2-乙基) | Bip(2-乙基) |
240 | H A E | G T F | T S D | Bip(2-乙基,4-氧甲基)) | Bip |
241 | H A E | G T Phe(2氯) | T S D | Bip(2-甲基) | Bip(2-甲基) |
242 | H A E | G T F | T S D | Bip(2-乙基,2’-甲基) | Bip(2,2’-二甲基) |
243 | H A γ-羧基-Glu | G T F | T S D | Bip(2-甲基) | Bip(2-甲基) |
244 | H A C | G T F | T S D | Bip(2-甲基) | Bip(2-甲基) |
245 | H ala E | G Nle L-α-甲基-Phe | T S D | Bip(2-乙基) | Bip(2-甲基) |
246 | H L-硫 E代Pro | G T F | T S D | Bip | Bip |
247 | H A E | G T F | T S D | Bip | Bip(2,2’-二甲基) |
248 | H A E | G T F | T S D | Bip(2-甲基) | Bip(2,2’-二甲基) |
249 | H A E | G T F | T S D | Bip(2’-甲基) | Bip(2-甲基) |
250 | H A E | G T F | T S D | Bip | Bip(2’-甲基) |
251 | H A E | G T F | T S D | Bip(2-甲基) | Bip(2’-甲基) |
252 | H A E | G T F | T S D | Bip(2’-甲基) | Bip |
253 | H Aib E | G Nle Phe(五氟) | T S D | bip(2’-甲基) | Bip(2-甲基) |
254 | H A E | G T F | T S D | Bip(2’-甲基) | Bip(2,2’-二甲基) |
255 | H A E | G T F | T S D | Bip(2’-甲基) | Bip(2’-甲基) |
256 | H A E | G T F | T S D | Bip(2,2’-二甲基) | Bip |
257 | H A E | G T F | T S D | Bip(2,2’-二甲基) | Bip(2-甲基) |
258 | H A E | G T F | T S D | Bip(2,2’-二甲基) | Bip(2-乙基) |
259 | H A E | G T F | T S D | Bip(2,2’-二甲基) | Bip(2,2’-二甲基) |
260 | H A E | G T F | T S D | Bip(2-甲基) | Phe(4-正丁基) |
261 | H A E | G T F | T S D | Bip(2-甲基) | Phe(3-苯基) |
262 | H A E | G T F | T S D | Bip(2-甲基) | Phe(4-环己基) |
263 | H A E | G T F | T S D | Bip(2-甲基) | Phe(4-苯氧基) |
264 | H A E | G T F | T S D | Phe(4-正丁基) | Bip(2-甲基) |
265 | H A E | G T F | T S D | Phe(4-环己基) | Bip(2-甲基) |
266 | H A E | G T F | T S D | Phe(4-苯氧基) | Bip(2-甲基) |
267 | H A D | G T Phe(3-氟) | T S D | Bip(2-甲基) | Bip(2-甲基) |
268 | H A D | G T Phe(4-氟) | T S D | Bip(2-甲基) | Bip(2-甲基) |
269 | H A D | G T Phe(3,4-二氟) | T S D | Bip(2-甲基) | Bip(2-甲基) |
270 | H A D | G T Phe(3,5-二氟) | T S D | Bip(2-甲基) | Bip(2-甲基) |
271 | H A D | G T Phe(3,4,5-三氟) | T S D | Bip(2-甲基) | Bip(2-甲基) |
272 | H ala D | G Nle F | T H D | Bip(2-甲基) | Bip(2-甲基) |
273 | H ala D | G T Phe(五氟) | T H D | Bip(2-甲基) | Bip(2-甲基) |
274 | H ala E | G Nle Phe(五氟) | T H D | Bip(2-甲基) | Bip(2-甲基) |
275 | H A H | G Nle Phe(五氟) | T H D | Bip(2-甲基) | Bip(2-甲基) |
276 | H A D | G Nle Phe(五氟) | T S D | Bip(2,4-二氧甲基) | Bip(2-甲基) |
277 | H A E | G T F | T S D | Bip(2-甲基,4-氧甲基) | Bip(3,4-亚甲基二氧基) |
278 | H A E | G T F | T S D | Bip(2-乙基) | Bip(3,4-亚甲基二氧基) |
279 | H A D | G T F | T S D | Bip(2,4-二-氧甲基) | 4-(1-萘基)-Phe |
280 | H A E | G T F | T S D | Bip(2-甲基,4-氧甲基) | 4-(1-萘基)-Phe |
281 | H A D | G T F | T S D | Bip(2,4-二-氧甲基) | Bip(4-氧甲基) |
282 | H A E | G T F | T S D | Bip(2-甲基,4-氧甲基) | Bip(4-氧甲基) |
283 | H A E | G T F | T S D | Bip(2,4-二-氧甲基) | Bip(4-甲基) |
284 | H A E | G T F | T S D | Bip(2-甲基,4-氧甲基) | Bip(4-甲基) |
285 | H A D | G T F | T S D | Bip(2,4-二-氧甲基) | Bip(2,4-二-氧甲基) |
286 | H A E | G T F | T S D | Bip(2-甲基,4-氧甲基) | Bip(2-甲基,4-氧甲基) |
287 | H A D | G T F | T S D | Bip(2,4-二-氧甲基) | Bip(2,4-二-氧甲基) |
288 | H A E | G T F | T S D | Bip(2,4-二-氧甲基) | Bip(3-甲基) |
289 | H A E | G T F | T S D | Bip(2-甲基,4-氧甲基) | Bip(3-甲基) |
290 | H A 4-噻唑基Ala | G T F | T S D | Bip(2-甲基) | Bip(2-甲基) |
291 | H ala D | G Nle Phe(五氟) | T H D | Bip(2-甲基) | Bip(2-甲基) |
292 | H A E | G T F | T S D | Bip(2-乙基,4,5-亚 | Bip(2-甲基) |
甲基二氧基) | |||||
293 | H N-甲 E基-Ala | G Nle Phe(五氟) | T H D | Bip(2-乙基) | Bip(2-甲基) |
294 | H N-甲 D基-Ala | G Nle Phe(五氟) | T S D | Bip(2-甲基) | Bip(2-甲基) |
295 | H N-甲 D基-Ala | G T Phe(五氟) | T S D | Bip(2-甲基) | Bip(2-甲基) |
296 | H N-甲 E基-Ala | G Nle Phe(五氟) | T H D | Bip(2-甲基) | Bip(2-甲基) |
297 | H N-甲 E基-Ala | G T Phe(五氟) | T S D | Bip(2-甲基) | Bip(2-甲基) |
298 | H sarcos Eyl | G T F | T S D | Bip(2-甲基) | Bip(2-甲基) |
299 | H A E | G T F | T S D | Bip(3-CH2NH2) | Bip(2-甲基) |
300 | H A E | G T F | T S D | Bip(2-CH2NH2) | Bip(2-甲基) |
301 | H A E | G T F | T S D | Bip(4-CH2NH2) | Bip(2-甲基) |
302 | H A E | G T F | T S D | Bip(3-CH2-COOH) | Bip(2-甲基) |
303 | H A E | G T F | T S D | Bip(2-甲基) | Bip(2’-CH2-COOH) |
304 | H A E | G T F | T S D | Bip(2-甲基) | (D,L)-Bip(2-CH2-COOH) |
305 | H A E | G T F | T S D | Bip(2-甲基) | Bip(4-CH2-COOH) |
306 | H A E | G T F | T S D | Bip(2-甲基) | Bip(3-CH2-COOH) |
307 | H A E | G T F | T S D | Bip(2-甲基) | Bip(3-CH2NH2) |
308 | H A E | G T F | T S D | Bip(2-甲基) | Bip(4-CH2NH2) |
309 | H A E | G T F | T S D | Bip(2-甲基) | Bip(2-CH2NH2) |
310 | H A E | G T F | T S D | Phe[4-(1-炔丙基)] | Bip(2-甲基) |
311 | H A E | G T F | T S D | Phe[4-(1-丙烯基)] | Bip(2-甲基) |
312 | H A asp | G T L-α-甲基-Phe | T S D | Bip(2-乙基) | Bip(2-甲基) |
313 | H A D | G thr L-α-甲基-Phe | T S D | Bip(2-乙基) | Bip(2-甲基) |
314 | H A D | G T L-α-甲基-Phe | T S asp | Bip(2-乙基) | Bip(2-甲基) |
315 | H A D | G T L-α-甲基-Phe | T S D | Bip(2-乙基) | Bip(2-甲基) |
316 | H ala asp | G T L-α-甲基-Phe | T S D | Bip(2-乙基) | Bip(2-甲基) |
317 | H Aib D | G T L-α-甲基-Phe | Thr S D | Bip(2-乙基) | Bip(2-甲基) |
318 | H Aib D | G T L-α-甲基-Phe | T S asp | Bip(2-乙基) | Bip(2-甲基) |
319 | H ala D | G Nle Phe(五氟) | T S D | Bip(2-甲基) | Bip(2-甲基) |
320 | H ala D | G Nle Phe(五氟) | T S D | Bip(2-乙基) | Bip(2-甲基) |
321 | H ala D | G Nle Phe(五氟) | T S D | Bip(2-甲基) | Bip(2-甲基) |
322 | H ala D | G Nle Phe(五氟) | T S D | Bip(2-甲基) | Bip(2-乙基) |
323 | H Aib D | G Nle Phe(五氟) | T S D | bip(2-甲基) | Bip(2-甲基) |
324 | H Aib D | G Nle Phe(五氟) | T S D | bip(2-乙基) | Bip(2-甲基) |
325 | H Aib D | G Nle Phe(五氟) | T S D | Bip(2-甲基) | Bip(2-甲基) |
326 | H Aib D | G Nle Phe(五氟) | T S D | Bip(2-甲基) | Bip(2-乙基) |
327 | H A E | G T F | T S D | Bip(2-甲基) | (D,L)-α-甲基-Bip |
328 | H A E | G T F | T S D | Bip | (D,L)-α-甲基-Bip |
329 | H A D | G 同分 L-α-甲基异构 -Phe的Thr | T S D | Bip(2-乙基) | Bip(2-甲基) |
330 | H A D | G T L-α-甲基-Phe | 同分异 S D构的-Thr | Bip(2-乙基) | Bip(2-甲基) |
331 | H A D | G T L-α-甲基-Phe | T hSer D | Bip(2-乙基) | Bip(2-甲基) |
332 | H A D | G T L-α-甲基-Phe | T T D | Bip(2-乙基) | Bip(2-甲基) |
333 | H A D | G T L-α-甲基-Phe | T S E | Bip(2-乙基) | Bip(2-甲基) |
334 | H A E | G Nle F | T S D | Bip(2-乙基) | Bip(2-甲基) |
335 | H A asp | G T L-α-甲基-Phe | T S D | Bip(2-乙基) | Bip(2-甲基) |
336 | H Aib D | G thr L-α-甲基-Phe | T S D | Bip(2-乙基) | Bip(2-甲基) |
337 | H Aib D | G T L-α-甲基-Phe | thr S D | Bip(2-乙基) | Bip(2-甲基) |
338 | H Aib D | G T L-α-甲基-Phe | T S asp | Bip(2-乙基) | Bip(2-甲基) |
339 | H A D | G T L-α-甲基-Phe | T S D | Bip(2-乙基)-NH-[2-(五-氟-苯基)乙基) | |
340 | H A D | G Nle L-α-甲基 | T S D | Bip(2-乙基) |
-Phe | -NH-[2-(五-氟-苯基)乙基] | ||||
34l | H Aib E | G T L-α-甲基-Phe | T S D | Bip(2-乙基)-NH-[2-(五-氟-苯基)乙基] | |
342 | H Aib D | G Nle L-α-甲基-Phe | T S D | Bip(2-乙基)-NH-[2-(五-氟-苯基)乙基] | |
343 | H Aib asp | G T L-α-甲基-Phe | T S D | Bip(2-乙基) | Bip(2-甲基) |
344 | H ala E | G T L-α-甲基-Phe | T S D | Bip(2-乙基) | Bip(2-甲基) |
345 | H ala E | G T L-Phe(2,6-二氟) | T S D | Bip(2-乙基) | Bip(2-甲基) |
346 | H N-甲 E基-Ala | G T L-α-甲基-Phe | T S D | Bip(2-乙基) | Bip(2-甲基) |
347 | H A N-甲基-Glu | G T L-α-甲基-Phe | T S D | Bip(2-乙基) | Bip(2-甲基) |
348 | H A E | N- T L-α-甲基甲 -Phe基Gly | T S D | Bip(2-乙基) | Bip(2-甲基) |
349 | H A D | G Nle (D,L)-α-甲基-Phe(五氟) | T S D | Bip(2-乙基,4-氧甲基) | Bip(2-甲基) |
350 | H ala D | G Nle (D,L)-α-甲基-Phe(五氟) | T S D | Bip(2-乙基,4-氧甲基) | Bip(2-甲基) |
351 | H Aib D | G Nle (D,L)-α-甲基-Phe(五氟) | T S D | Bip(2-乙基,4-氧甲基) | Bip(2-甲基) |
352 | H ala E | G T D-Phe(2,6-二氟) | T S D | Bip(2-乙基) | Bip(2-甲基) |
353 | H Aib D | G T D-Phe(2,6-二氟) | T S D | Bip(2-乙基) | Bip(2-甲基) |
354 | H A E | G T (D,L)-α-甲基-Phe(五氟) | T S D | Bip(2-乙基,4-氧甲基) | Bip(2-甲基) |
355 | H A D | G T (D,L)-α-甲基-Phe(五氟) | T S D | Bip(2-乙基,4-氧甲基) | Bip(2-甲基) |
356 | H ala E | G T (D,L)-α-甲基-Phe(五氟) | T S D | Bip(2-乙基,4-氧甲基) | Bip(2-甲基) |
357 | H A D | G T L-α-甲基-Phe | T S D | Bip(2-乙基) | bip(2-乙基) |
358 | H Aib D | G T L-α-甲基 | T S D | Bip(2-乙基) | bip(2-甲基) |
-Phe | |||||
359 | H A E | G T L-α-甲基-Phe | T S D | Bip(3-OH) | Bip(2-甲基) |
360 | H A E | G T L-α-甲基-Phe | T S D | Bip(4-OH) | Bip(2-甲基) |
361 | H A E | G T L-α-甲基-Phe | T S D | Bip(2-氧乙基) | Bip(2-甲基) |
362 | H A E | G T L-α-甲基-Phe | T S D | Bip(3-氧乙基) | Bip(2-甲基) |
363 | H A E | G T L-α-甲基-Phe | T S D | Bip(3-OCF3) | Bip(2-甲基) |
364 | H A E | G T L-α-甲基-Phe | T S D | Bip(3-NO2) | Bip(2-甲基) |
365 | H A E | G T L-α-甲基-Phe | T S D | Bip(3-CF3) | Bip(2-甲基) |
366 | H A E | G T L-α-甲基-Phe | T S D | Bip(3-氟) | Bip(2-甲基) |
367 | H A E | G T L-α-甲基-Phe | T S D | Bip(3-氯) | Bip(2-甲基) |
368 | H A E | G T L-α-甲基-Phe | T S D | Bip(3-Ph) | Bip(2-甲基) |
369 | H A E | G T L-α-甲基-Phe | T S D | Bip(3-乙基) | Bip(2-甲基) |
370 | H A E | G T L-α-甲基-Phe | T S D | Bip(3-异丙基) | Bip(2-甲基) |
371 | H A E | G T L-α-甲基-Phe | T S D | Bip(4-异丙基) | Bip(2-甲基) |
372 | H A E | G T L-α-甲基 | T S D | Bip(4-丙基) | Bip(2-甲基) |
-Phe | |||||
373 | H A E | G T L-α-甲基-Phe | T S D | Bip(3-丙基) | Bip(2-甲基) |
374 | H A E | G T L-α-甲基-Phe | T S D | Bip(2,5-二氯) | Bip(2-甲基) |
375 | H A E | G T L-α-甲基-Phe | T S D | Bip(2,5-二氟) | Bip(2-甲基) |
376 | H A E | G T L-α-甲基-Phe | T S D | Bip(3,4-二氟) | Bip(2-甲基) |
377 | H A E | G T L-α-甲基-Phe | T S D | Bip(3,4-二氯) | Bip(2-甲基) |
378 | H A E | G T L-α-甲基-Phe | T S D | Bip(2,3-二氯) | Bip(2-甲基) |
379 | H A E | G T L-α-甲基-Phe | T S D | Bip(3-NHAc) | Bip(2-甲基) |
380 | H A E | G T L-α-甲基-Phe | T S D | Bip(4-NHAc) | Bip(2-甲基) |
381 | H A E | G Aoc L-α-甲基-Phe | T S D | Bip(2-乙基) | Bip(2-甲基) |
382 | H A D | G Nle F | T S D | Bip(2-乙基) | Bip(2-甲基) |
383 | H ala E | G T L-Phe(2-氟) | T S D | Bip(2-乙基) | Bip(2-甲基) |
384 | H Aib D | G Nle (D,L)-α-乙基-Phe | T S D | Bip(2-乙基) | Bip(2-甲基) |
385 | H Aib D | G T L-α-甲基-Phe | T (D,L)- Dα-甲基-Ser | Bip(2-乙基) | Bip(2-甲基) |
386 | H A D | G T L-α-甲基 | T S D | Bip(2-乙基,4-氧甲 | Bip(2-甲基) |
-Phe(2,6-二氟) | 基) | ||||
387 | H A E | G T L-α-甲基-Phe | T S D | Bip(4-叔丁基) | Bip(2-甲基) |
388 | H ala E | G Nle L-α-甲基-Phe(2,6-二氟) | T S D | Bip(2-乙基,4-氧甲基) | Bip(2-甲基) |
389 | H ala D | G Nle L-α-甲基-Phe(2,6-二氟) | T S D | Bip(2-乙基,4-氧甲基) | Bip(2-甲基) |
390 | H Aib E | G Nle L-α-甲基-Phe(2,6-二氟) | T S D | Bip(2-乙基,4-氧甲基) | Bip(2-甲基) |
391 | H Aib D | G Nle L-α-甲基-Phe(2,6-二氟) | T S D | Bip(2-乙基,4-氧甲基) | Bip(2-甲基) |
392 | H A D | G Nle L-α-甲基-Phe(2,6-二氟) | T S D | Bip(2-乙基) | Bip(2-甲基) |
393 | H A D | G T F | T S D | Bip(2-乙基) | Bip(2-甲基) |
化合物# | A | Xaa1 Xaa2 Xaa3 Xaa4 Xaa5 Xaa6 Xaa7 Xaa8 Xaa9 | Y | Z |
1 | 乙酰基 | H A E G T F T S D | Bip | Bip |
2 | β-Ala | H A E G T F T S D | Bip | Bip |
3 | Ahx | H A E G T F T S D | Bip | Bip |
4 | D | H A E G T F T S D | Bip | Bip |
5 | E | H A E G T F T S D | Bip | Bip |
6 | F | H A E G T F T S D | Bip | Bip |
7 | G | H A E G T F T S D | Bip | Bip |
8 | K | H A E G T F T S D | Bip | Bip |
9 | Nva | H A E G T F T S D | Bip | Bip |
10 | N | H A E G T F T S D | Bip | Bip |
11 | R | H A E G T F T S D | Bip | Bip |
12 | S | H A E G T F T S D | Bip | Bip |
13 | T | H A E G T F T S D | Bip | Bip |
14 | V | H A E G T F T S D | Bip | Bip |
15 | W | H A E G T F T S D | Bip | Bip |
16 | Y | H A E G T F T S D | Bip | Bip |
17 | 己内酰胺 | H A E G T F T S D | Bip | Bip |
18 | Bip | H A E G T F T S D | Bip | Bip |
19 | Ser(Bzl) | H A E G T F T S D | Bip | Bip |
20 | 3-吡啶基丙氨酸 | H A E G T F T S D | Bip | Bip |
21 | Phe(4-甲基) | H A E G T F T S D | Bip | Bip |
22 | Phe(五氟) | H A E G T F T S D | Bip | Bip |
化合物# | R-CH2- | Xaa2 Xaa3 Xaa4 Xaa5 Xaa6 Xaa7 Xaa8 Xaa9 | Y | Z |
1 | 4-甲基苯甲基 | H A E G T F T S D | Bip(2-Me) | Bip(2-Me) |
2 | 4-氟苯甲基 | H A E G T F T S D | Bip(2-Me) | Bip(2-Me) |
3 | 丙基 | H A E G T F T S D | Bip(2-Me) | Bip(2-Me) |
4 | 己基 | H A E G T F T S D | Bip(2-Me) | Bip(2-Me) |
5 | 环己基甲基 | H A E G T F T S D | Bip(2-Me) | Bip(2-Me) |
6 | 6-羟戊基 | H A E G T F T S D | Bip(2-Me) | Bip(2-Me) |
7 | 2-噻吩基甲基 | H A E G T F T S D | Bip(2-Me) | Bip(2-Me) |
8 | 3-噻吩基甲基 | H A E G T F T S D | Bip(2-Me) | Bip(2-Me) |
9 | 五氟苯甲基 | H A E G T F T S D | Bip(2-Me) | Bip(2-Me) |
10 | 2-萘基甲基 | H A E G T F T S D | Bip(2-Me) | Bip(2-Me) |
11 | 4-二苯基甲基 | H A E G T F T S D | Bip(2-Me) | Bip(2-Me) |
12 | 9-蒽基甲基 | H A E G T F T S D | Bip(2-Me) | Bip(2-Me) |
13 | 苯甲基 | H A E G T F T S D | Bip(2-Me) | Bip(2-Me) |
14 | (S)-(2-氨基-3-苯基)丙基 | H A E G T F T S D | Bip(2-Me) | Bip(2-Me) |
15 | 甲基 | H A E G T F T S D | Bip | Bip |
16 | 苯甲基 | H A E G T F T S D | Bip | Bip |
17 | 2-氨乙基 | H A E G T F T S D | Bip(2-Me) | Bip(2-Me) |
18 | (S)-2-氨丙基 | H A E G T F T S D | Bip(2-Me) | Bip(2-Me) |
化合物# | Xaa1 Xaa2 Xaa3 Xaa4 Xaa5 Xaa6 Xaa7 Xaa8 Xaa9 | Y | Z | B |
1 | H A E G T F T S D | Bip | 2-Nal | W |
2 | H A E G T F T S D | Bip | Phe(五氟) | 2-Nal |
3 | H A E G T F T S D | Bip | Phe(五氟) | Phe(五氟) |
4 | H A E G T F T S D | Bip | Phe(五氟) | Ser(Bzl) |
5 | H A E G T F T S D | Bip | Phe(五氟) | Phe(4-NO2) |
6 | H A E G T F T S D | Bip | Phe(五氟) | 3-吡啶基丙氨酸 |
7 | H A E G T F T S D | Bip | Phe(五氟) | Nva |
8 | H A E G T F T S D | Bip | Phe(五氟) | K |
9 | H A E G T F T S D | Bip | Phe(五氟) | D |
10 | H A E G T F T S D | Bip | Phe(五氟) | S |
11 | H A E G T F T S D | Bip | Phe(五氟) | H |
12 | H A E G T F T S D | Bip | Phe(五氟) | Y |
13 | H A E G T F T S D | Bip | Phe(五氟) | W |
14 | H A E G T F T S D | Bip | Phe(五氟) | F |
15 | H A E G T F T S D | 2-Nal | Phe(五氟) | W |
16 | H A E G T F T S D | Bip | Bip | Bip |
17 | H A E G T F T S D | Bip | Bip | Nva |
18 | H A E G T F T S D | Bip(2-Me) | Bip(2-Me) | Ser |
19 | H A E G T F T S D | Bip(2-Me) | Bip(2-Me) | Gly-OH |
20 | H A E G T F T S D | Bip(2-Me) | Bip(2-Me) | β-Ala-OH |
21 | H A E G T F T S D | Bip(2-Me) | Bip(2-Me) | GABA-OH |
22 | H A E G T F T S D | Bip(2-Me) | Bip(2-Me) | APA-OH |
Claims (61)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US34201501P | 2001-10-18 | 2001-10-18 | |
US60/342,015 | 2001-10-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN1630709A true CN1630709A (zh) | 2005-06-22 |
Family
ID=23339970
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA028205588A Pending CN1630709A (zh) | 2001-10-18 | 2002-10-18 | 人胰高血糖素样多肽-1模拟物和它们在治疗糖尿病和相关状况中的应用 |
Country Status (21)
Country | Link |
---|---|
US (3) | US7238670B2 (zh) |
EP (1) | EP1572892A4 (zh) |
JP (1) | JP2005514337A (zh) |
KR (1) | KR20040054729A (zh) |
CN (1) | CN1630709A (zh) |
AU (1) | AU2002348469B2 (zh) |
BR (1) | BR0213377A (zh) |
CA (1) | CA2463908A1 (zh) |
GE (1) | GEP20063908B (zh) |
HR (1) | HRP20040343A2 (zh) |
HU (1) | HUP0700151A2 (zh) |
IL (1) | IL160917A0 (zh) |
IS (1) | IS7185A (zh) |
MX (1) | MXPA04003553A (zh) |
NO (1) | NO20041203L (zh) |
NZ (1) | NZ531788A (zh) |
PL (1) | PL377687A1 (zh) |
RU (1) | RU2353625C2 (zh) |
WO (1) | WO2003033671A2 (zh) |
YU (1) | YU31004A (zh) |
ZA (1) | ZA200402846B (zh) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102250315A (zh) * | 2011-05-10 | 2011-11-23 | 郑州大学 | 氨基酸衍生环氧树脂 |
CN102920658A (zh) * | 2012-11-02 | 2013-02-13 | 艾韦特(溧阳)医药科技有限公司 | 与glp-1类似物和聚乙二醇结合的脂质体及其制备方法 |
CN105683153A (zh) * | 2013-09-17 | 2016-06-15 | 维克图斯生物系统有限公司 | 用于治疗高血压和/或纤维化的组合物 |
CN107080836A (zh) * | 2009-07-06 | 2017-08-22 | 赛诺菲-安万特德国有限公司 | 含有甲硫氨酸的水性胰岛素制备物 |
WO2021238965A1 (zh) * | 2020-05-28 | 2021-12-02 | 杭州中美华东制药有限公司 | (s)-2-氨基-3-(4-(2,3-二甲基吡啶-4-基)苯基丙酸甲酯及其盐的制备方法 |
CN114591418A (zh) * | 2020-12-04 | 2022-06-07 | 南京大学 | PPARγ蛋白的第166位苏氨酸磷酸化修饰及其应用 |
Families Citing this family (82)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7238671B2 (en) | 2001-10-18 | 2007-07-03 | Bristol-Myers Squibb Company | Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions |
PL377687A1 (pl) * | 2001-10-18 | 2006-02-06 | Bristol-Myers Squibb Company | Środki naśladujące ludzki peptyd glukagonopodobny typu 1 i ich zastosowanie w leczeniu cukrzycy i stanów związanych z cukrzycą |
AU2003264256A1 (en) * | 2002-09-04 | 2004-03-29 | Dsm Ip Assets B.V. | A nutritional and therapeutic composition of an insulin sensitizer and a peptide fraction |
EP1617888B1 (en) | 2003-04-23 | 2019-06-12 | Valeritas, Inc. | Hydraulically actuated pump for long duration medicament administration |
KR101243648B1 (ko) | 2003-11-20 | 2013-03-14 | 노보 노르디스크 에이/에스 | 제조 및 주사 장치용에 최적인 프로필렌 글리콜 함유펩티드 제제 |
JP2007514752A (ja) * | 2003-12-16 | 2007-06-07 | ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス | Glp−1医薬組成物 |
PL1750862T3 (pl) | 2004-06-04 | 2011-06-30 | Teva Pharma | Kompozycja farmaceutyczna zawierająca irbesartan |
US7145040B2 (en) * | 2004-07-02 | 2006-12-05 | Bristol-Myers Squibb Co. | Process for the preparation of amino acids useful in the preparation of peptide receptor modulators |
US9089636B2 (en) * | 2004-07-02 | 2015-07-28 | Valeritas, Inc. | Methods and devices for delivering GLP-1 and uses thereof |
US7534763B2 (en) | 2004-07-02 | 2009-05-19 | Bristol-Myers Squibb Company | Sustained release GLP-1 receptor modulators |
TW200611704A (en) * | 2004-07-02 | 2006-04-16 | Bristol Myers Squibb Co | Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions |
AR051446A1 (es) | 2004-09-23 | 2007-01-17 | Bristol Myers Squibb Co | Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2) |
US7635699B2 (en) | 2004-12-29 | 2009-12-22 | Bristol-Myers Squibb Company | Azolopyrimidine-based inhibitors of dipeptidyl peptidase IV and methods |
US7589088B2 (en) | 2004-12-29 | 2009-09-15 | Bristol-Myers Squibb Company | Pyrimidine-based inhibitors of dipeptidyl peptidase IV and methods |
DOP2006000008A (es) * | 2005-01-10 | 2006-08-31 | Arena Pharm Inc | Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1 |
US7521557B2 (en) | 2005-05-20 | 2009-04-21 | Bristol-Myers Squibb Company | Pyrrolopyridine-based inhibitors of dipeptidyl peptidase IV and methods |
AR053495A1 (es) * | 2005-05-26 | 2007-05-09 | Bristol Myers Squibb Co | Moduladores del peptido 1 similar al glucagon humano y su uso en el tratamiento de la diabetes y condiciones relacionadas |
EP2497781A1 (en) * | 2005-09-08 | 2012-09-12 | Trustees Of Tufts College | Stabilized GLP-1 analogs |
ZA200802857B (en) | 2005-09-14 | 2009-09-30 | Takeda Pharmaceutical | Dipeptidyl peptidase inhibitors for treating diabetes |
KR101368988B1 (ko) | 2005-09-16 | 2014-02-28 | 다케다 야쿠힌 고교 가부시키가이샤 | 디펩티딜 펩티다제 억제제 |
US7488725B2 (en) | 2005-10-31 | 2009-02-10 | Bristol-Myers Squibb Co. | Pyrrolidinyl beta-amino amide-based inhibitors of dipeptidyl peptidase IV and methods |
WO2007051987A1 (en) * | 2005-11-01 | 2007-05-10 | Activotec Spp Limited | Insulinotropic compounds and uses thereof |
CA2628241C (en) | 2005-11-07 | 2016-02-02 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting physiological solubility and stability |
GB0526291D0 (en) | 2005-12-23 | 2006-02-01 | Prosidion Ltd | Therapeutic method |
US20070238669A1 (en) * | 2006-01-11 | 2007-10-11 | Bristol-Myers Squibb Company | Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes related conditions |
CA2638800A1 (en) * | 2006-02-22 | 2007-09-07 | Merck & Co., Inc. | Oxyntomodulin derivatives |
PE20080168A1 (es) * | 2006-03-23 | 2008-02-25 | Bristol Myers Squibb Co | Preparacion enzimatica de (s)-aminoacido a partir del (r,s)-aminoacido o a partir del ceto acido |
WO2007112347A1 (en) | 2006-03-28 | 2007-10-04 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
ES2566058T3 (es) | 2006-03-30 | 2016-04-08 | Valeritas, Inc. | Dispositivo de suministro de fluidos de múltiples cartuchos |
PL1971862T3 (pl) * | 2006-04-11 | 2011-04-29 | Arena Pharm Inc | Sposoby stosowania receptora GPR119 w celu identyfikacji związków przydatnych w zwiększeniu masy kostnej osobnika |
PE20071221A1 (es) | 2006-04-11 | 2007-12-14 | Arena Pharm Inc | Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas |
MX2008013459A (es) * | 2006-04-20 | 2008-10-30 | Amgen Inc | Composiciones de anticuerpos glucagon/compuesto de peptido 1 similar al glucagon (glp-1). |
US20100022457A1 (en) * | 2006-05-26 | 2010-01-28 | Bristol-Myers Squibb Company | Sustained release glp-1 receptor modulators |
US7919598B2 (en) | 2006-06-28 | 2011-04-05 | Bristol-Myers Squibb Company | Crystal structures of SGLT2 inhibitors and processes for preparing same |
US20080044326A1 (en) * | 2006-07-04 | 2008-02-21 | Esencia Co., Ltd. | Sterilizer for baby products |
US8324383B2 (en) | 2006-09-13 | 2012-12-04 | Takeda Pharmaceutical Company Limited | Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile |
TWI430806B (zh) | 2006-09-13 | 2014-03-21 | Smithkline Beecham Corp | 用於投與長效降血糖藥劑之方法 |
AU2007323035B2 (en) | 2006-10-03 | 2011-11-24 | Cadila Healthcare Limited | Antidiabetic compounds |
TW200838536A (en) | 2006-11-29 | 2008-10-01 | Takeda Pharmaceutical | Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor |
AU2008205229B2 (en) * | 2007-01-05 | 2014-03-27 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting enhanced solubility in physiological pH buffers |
KR20150116465A (ko) | 2007-02-15 | 2015-10-15 | 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 | 글루카곤/glp-1 수용체 공동-항진물질 |
US8093236B2 (en) | 2007-03-13 | 2012-01-10 | Takeda Pharmaceuticals Company Limited | Weekly administration of dipeptidyl peptidase inhibitors |
AR065809A1 (es) | 2007-03-22 | 2009-07-01 | Bristol Myers Squibb Co | Formulaciones farmaceuticas que contienen un inhibidor sglt2 |
PE20090696A1 (es) | 2007-04-20 | 2009-06-20 | Bristol Myers Squibb Co | Formas cristalinas de saxagliptina y procesos para preparar las mismas |
CA2707861A1 (en) | 2007-10-30 | 2009-05-07 | Indiana University Research And Technology Corporation | Glucagon antagonists |
CA2702289A1 (en) * | 2007-10-30 | 2009-05-07 | Indiana University Research And Technology Corporation | Compounds exhibiting glucagon antagonist and glp-1 agonist activity |
MX2010006287A (es) * | 2007-12-11 | 2010-10-26 | Cadila Healthcare Ltd | Peptidomimeticos con actividades antagonistas de glucagon y agonistas del peptido 1 similar al glucagon. |
WO2009099763A1 (en) * | 2008-01-30 | 2009-08-13 | Indiana University Research And Technology Corporation | Ester-based peptide prodrugs |
EP2146210A1 (en) | 2008-04-07 | 2010-01-20 | Arena Pharmaceuticals, Inc. | Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY |
NZ589847A (en) * | 2008-06-17 | 2013-01-25 | Univ Indiana Res & Tech Corp | Glucagon/glp-1 receptor co-agonists |
JP5753779B2 (ja) * | 2008-06-17 | 2015-07-22 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation | 生理学的pHの緩衝液中で向上した溶解性及び安定性を示すグルカゴン類縁体 |
EP2952202B1 (en) * | 2008-06-17 | 2017-10-18 | Indiana University Research and Technology Corporation | Gip-based mixed agonists for treatment of metabolic disorders and obesity |
PL2373681T3 (pl) | 2008-12-10 | 2017-07-31 | Glaxosmithkline Llc | Kompozycje farmaceutyczne albiglutydu |
AR074811A1 (es) | 2008-12-19 | 2011-02-16 | Univ Indiana Res & Tech Corp | Profarmaco de peptido de la superfamilia de glucagon basados en amida |
KR20120087875A (ko) | 2009-06-16 | 2012-08-07 | 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 | Gip 수용체-활성 글루카곤 화합물 |
EP2491054A2 (en) | 2009-10-22 | 2012-08-29 | Cadila Healthcare Limited | Short chain peptidomimetics based orally active glp-1 agonist and glucagon receptor antagonist |
CA2780938A1 (en) | 2009-11-13 | 2011-05-19 | Bristol-Myers Squibb Company | Reduced mass metformin formulations |
PL2498759T3 (pl) | 2009-11-13 | 2019-03-29 | Astrazeneca Ab | Formulacje tabletek o natychmiastowym uwalnianiu |
PT2498758T (pt) | 2009-11-13 | 2018-10-23 | Astrazeneca Uk Ltd | Formulações de comprimido bicamada |
RU2554087C2 (ru) | 2009-12-18 | 2015-06-27 | Айденикс Фармасьютикалз, Инк. | 5,5-конденсированные ариленовые или гетероариленовые ингибиторы вируса гепатита с |
EP2512503A4 (en) | 2009-12-18 | 2013-08-21 | Univ Indiana Res & Tech Corp | COAGONISTS OF GLUCAGON / GLP-1 RECEPTOR |
MX2012008603A (es) | 2010-01-27 | 2013-01-25 | Univ Indiana Res & Tech Corp | Conjugados de antagonista de glucagon-agonista de gip y composiciones para el tratamiento de desordenes metabolicos y obesidad. |
TWI562775B (en) | 2010-03-02 | 2016-12-21 | Lexicon Pharmaceuticals Inc | Methods of using inhibitors of sodium-glucose cotransporters 1 and 2 |
WO2011140176A1 (en) | 2010-05-04 | 2011-11-10 | Glaxosmithkline Llc | Methods for treating or preventing cardiovascular disorders and providing cardiovascular protection |
CA2797095A1 (en) | 2010-05-13 | 2011-11-17 | Indiana University Research And Technology Corporation | Glucagon superfamily peptides exhibiting nuclear hormone receptor activity |
CA2797089A1 (en) | 2010-05-13 | 2011-11-17 | Indiana University Research And Technology Corporation | Glucagon superfamily peptides exhibiting g protein-coupled receptor activity |
RU2557301C2 (ru) * | 2010-05-17 | 2015-07-20 | Бетта Фармасьютикалз Ко.,Лтд | Новые аналоги глюкагон-подобного пептида, композиция и способ применения |
WO2011163012A2 (en) | 2010-06-24 | 2011-12-29 | Indiana University Research And Technology Corporation | Amide based glucagon superfamily peptide prodrugs |
EP2588490B1 (en) | 2010-07-02 | 2017-02-22 | Angiochem Inc. | Short and d-amino acid-containing polypeptides for therapeutic conjugates and uses thereof |
BR112013015389A2 (pt) | 2010-12-22 | 2016-11-22 | Univ Indiana Res & Tech Corp | análogo de glucagon exibindo atividade de receptor gip |
TWI631963B (zh) | 2011-01-05 | 2018-08-11 | 雷西肯製藥股份有限公司 | 包含鈉-葡萄糖共同輸送體1與2之抑制劑的組合物與應用方法 |
RU2014101697A (ru) | 2011-06-22 | 2015-07-27 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | Коагонисты рецепторов глюкагона/glp-1 |
CN103857408B (zh) | 2011-06-22 | 2017-04-12 | 印第安那大学科技研究公司 | 胰高血糖素/glp‑1受体协同激动剂 |
RU2014117678A (ru) | 2011-11-17 | 2015-12-27 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | Пептиды глюкагонового суперсемейства, обладающие глюкокортикоидной рецепторной активностью |
EP2864351B1 (en) | 2012-06-21 | 2016-08-10 | Indiana University Research and Technology Corporation | Glucagon analogs exhibiting gip receptor activity |
WO2014081660A1 (en) | 2012-11-20 | 2014-05-30 | Lexicon Pharmaceuticals, Inc. | Inhibitors of sodium glucose cotransporter 1 |
US20160024169A1 (en) | 2013-03-14 | 2016-01-28 | Indiana University Research And Technology Corporation | Insulin-incretin conjugates |
WO2016049190A1 (en) | 2014-09-24 | 2016-03-31 | Indiana University Research And Technology Corporation | Incretin-insulin conjugates |
HRP20240485T1 (hr) | 2017-08-24 | 2024-07-05 | Novo Nordisk A/S | Pripravci glp-1 i njihova upotreba |
WO2020068661A1 (en) | 2018-09-26 | 2020-04-02 | Lexicon Pharmaceuticals, Inc. | Crystalline forms of n-(1 -((2-(dimethylamino)ethyl)amino)-2-m ethyl-1 -oopropan-2-yl)-4-(4-(2-methyl-5- (2s,3r,4r,5s,6r)-3,4,5-trihydroxy-6-(methylthio)tetrahydro-2h-pyran-2-yl)benzyl) phenl)butanamide and methods of their synthesis |
US20230082544A1 (en) | 2020-02-18 | 2023-03-16 | Novo Nordisk A/S | Pharmaceutical formulations |
US11806405B1 (en) | 2021-07-19 | 2023-11-07 | Zeno Management, Inc. | Immunoconjugates and methods |
Family Cites Families (90)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2019419A (en) * | 1931-05-11 | 1935-10-29 | Du Pont | Hydrogenation of pyridine bodies |
US3674836A (en) | 1968-05-21 | 1972-07-04 | Parke Davis & Co | 2,2-dimethyl-{11 -aryloxy-alkanoic acids and salts and esters thereof |
US4027009A (en) | 1973-06-11 | 1977-05-31 | Merck & Co., Inc. | Compositions and methods for depressing blood serum cholesterol |
JPS5612114B2 (zh) | 1974-06-07 | 1981-03-18 | ||
US4231938A (en) | 1979-06-15 | 1980-11-04 | Merck & Co., Inc. | Hypocholesteremic fermentation products and process of preparation |
MX7065E (es) | 1980-06-06 | 1987-04-10 | Sankyo Co | Un procedimiento microbiologico para preparar derivados de ml-236b |
US4450171A (en) | 1980-08-05 | 1984-05-22 | Merck & Co., Inc. | Antihypercholesterolemic compounds |
US4448784A (en) | 1982-04-12 | 1984-05-15 | Hoechst-Roussel Pharmaceuticals, Inc. | 1-(Aminoalkylphenyl and aminoalkylbenzyl)-indoles and indolines and analgesic method of use thereof |
US5354772A (en) | 1982-11-22 | 1994-10-11 | Sandoz Pharm. Corp. | Indole analogs of mevalonolactone and derivatives thereof |
US4499289A (en) | 1982-12-03 | 1985-02-12 | G. D. Searle & Co. | Octahydronapthalenes |
CA1327360C (en) | 1983-11-14 | 1994-03-01 | William F. Hoffman | Oxo-analogs of mevinolin-like antihypercholesterolemic agents |
EP0144726B2 (de) * | 1983-11-17 | 1995-05-24 | Akzo Nobel N.V. | Antimikrobielle Mischungen |
US4647476A (en) * | 1984-03-05 | 1987-03-03 | General Electric Company | Insulating glass body with electrical feedthroughs and method of preparation |
US4613610A (en) | 1984-06-22 | 1986-09-23 | Sandoz Pharmaceuticals Corp. | Cholesterol biosynthesis inhibiting pyrazole analogs of mevalonolactone and its derivatives |
US4686237A (en) | 1984-07-24 | 1987-08-11 | Sandoz Pharmaceuticals Corp. | Erythro-(E)-7-[3'-C1-3 alkyl-1'-(3",5"-dimethylphenyl)naphth-2'-yl]-3,5-dihydroxyhept-6-enoic acids and derivatives thereof |
US4647576A (en) | 1984-09-24 | 1987-03-03 | Warner-Lambert Company | Trans-6-[2-(substitutedpyrrol-1-yl)alkyl]-pyran-2-one inhibitors of cholesterol synthesis |
DE3581638D1 (de) | 1984-12-04 | 1991-03-07 | Sandoz Ag | Inden-analoga von mevalonolakton und ihre derivate. |
US4613810A (en) * | 1985-05-10 | 1986-09-23 | The United States Of America As Represented By The Secretary Of The Navy | High output programmable signal current source for low output impedance applications |
US4668794A (en) | 1985-05-22 | 1987-05-26 | Sandoz Pharm. Corp. | Intermediate imidazole acrolein analogs |
KR900001212B1 (ko) | 1985-10-25 | 1990-02-28 | 산도즈 파마슈티칼스 코오포레이숀 | 메바로노락톤 및 그것의 유도체의 헤테로사이클릭 유사체 및 그것의 생산방법 및 약학적인 그것의 용도 |
US5421992A (en) * | 1987-02-17 | 1995-06-06 | Chevron U.S.A. Inc. | Hydrocarbon conversion process using zeolite SSZ-25 |
FR2596393B1 (fr) | 1986-04-01 | 1988-06-03 | Sanofi Sa | Derives de l'acide hydroxy-3 dihydroxyoxophosphorio-4 butanoique, leur procede de preparation, leur application comme medicament et les compositions les renfermant |
US5614492A (en) | 1986-05-05 | 1997-03-25 | The General Hospital Corporation | Insulinotropic hormone GLP-1 (7-36) and uses thereof |
US4681893A (en) | 1986-05-30 | 1987-07-21 | Warner-Lambert Company | Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis |
ES2009918A6 (es) | 1987-05-22 | 1989-10-16 | Squibb & Sons Inc | Procedimiento para preparar inhibidores de hmg-coa-reductasa que contienen fosforo. |
US4759923A (en) | 1987-06-25 | 1988-07-26 | Hercules Incorporated | Process for lowering serum cholesterol using poly(diallylmethylamine) derivatives |
JP2569746B2 (ja) | 1987-08-20 | 1997-01-08 | 日産化学工業株式会社 | キノリン系メバロノラクトン類 |
US4871721A (en) | 1988-01-11 | 1989-10-03 | E. R. Squibb & Sons, Inc. | Phosphorus-containing squalene synthetase inhibitors |
US4924024A (en) | 1988-01-11 | 1990-05-08 | E. R. Squibb & Sons, Inc. | Phosphorus-containing squalene synthetase inhibitors, new intermediates and method |
NO177005C (no) | 1988-01-20 | 1995-07-05 | Bayer Ag | Analogifremgangsmåte for fremstilling av substituerte pyridiner, samt mellomprodukter til bruk ved fremstillingen |
US5506219A (en) | 1988-08-29 | 1996-04-09 | E. R. Squibb & Sons, Inc. | Pyridine anchors for HMG-CoA reductase inhibitors |
US5753675A (en) | 1989-03-03 | 1998-05-19 | Novartis Pharmaceuticals Corporation | Quinoline analogs of mevalonolactone and derivatives thereof |
FI94339C (fi) | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
JPH07242696A (ja) * | 1990-08-10 | 1995-09-19 | Enichem Partecipazioni Spa | 植物病原体に対して活性な抗菌性ペプチド、その使用法およびこれに関連するスクリーニング法 |
US5177080A (en) | 1990-12-14 | 1993-01-05 | Bayer Aktiengesellschaft | Substituted pyridyl-dihydroxy-heptenoic acid and its salts |
AU648140B2 (en) * | 1991-02-01 | 1994-04-14 | Virtual Drug Development, Inc. | Reverse antimicrobial peptides and antimicrobial compositions |
JP2648897B2 (ja) | 1991-07-01 | 1997-09-03 | 塩野義製薬株式会社 | ピリミジン誘導体 |
US5595872A (en) | 1992-03-06 | 1997-01-21 | Bristol-Myers Squibb Company | Nucleic acids encoding microsomal trigyceride transfer protein |
US5712396A (en) | 1992-10-28 | 1998-01-27 | Magnin; David R. | α-phosphonosulfonate squalene synthetase inhibitors |
US5516642A (en) * | 1992-11-16 | 1996-05-14 | Bristol-Myers Squibb Company | Polypeptides derived from major histocompatibility complex Class I antigen |
DK0638071T3 (da) * | 1992-12-28 | 1997-10-27 | Eisai Co Ltd | Heterocykliske carboxylsyrederivater, der bindes til retenoidreceptorer (RAR) |
US5594016A (en) | 1992-12-28 | 1997-01-14 | Mitsubishi Chemical Corporation | Naphthalene derivatives |
DE69324504T2 (de) | 1993-01-19 | 1999-08-26 | Warner Lambert Co | Stabilisierte, oral anzuwendende zusammensetzung enthaltend die verbindung ci-981 und verfahren |
US5739135A (en) | 1993-09-03 | 1998-04-14 | Bristol-Myers Squibb Company | Inhibitors of microsomal triglyceride transfer protein and method |
US5776983A (en) | 1993-12-21 | 1998-07-07 | Bristol-Myers Squibb Company | Catecholamine surrogates useful as β3 agonists |
US5488064A (en) | 1994-05-02 | 1996-01-30 | Bristol-Myers Squibb Company | Benzo 1,3 dioxole derivatives |
US5385929A (en) | 1994-05-04 | 1995-01-31 | Warner-Lambert Company | [(Hydroxyphenylamino) carbonyl] pyrroles |
US5612359A (en) | 1994-08-26 | 1997-03-18 | Bristol-Myers Squibb Company | Substituted biphenyl isoxazole sulfonamides |
US5491134A (en) | 1994-09-16 | 1996-02-13 | Bristol-Myers Squibb Company | Sulfonic, phosphonic or phosphiniic acid β3 agonist derivatives |
US5541204A (en) | 1994-12-02 | 1996-07-30 | Bristol-Myers Squibb Company | Aryloxypropanolamine β 3 adrenergic agonists |
US5620997A (en) | 1995-05-31 | 1997-04-15 | Warner-Lambert Company | Isothiazolones |
AU6966696A (en) | 1995-10-05 | 1997-04-28 | Warner-Lambert Company | Method for treating and preventing inflammation and atherosclerosis |
DE69636677D1 (de) | 1995-12-13 | 2006-12-14 | Univ California | Kristalle der mit einem Ligand komplexierten Ligandenbindedomäne des Schilddrüsenhormonrezeptors |
US5770615A (en) | 1996-04-04 | 1998-06-23 | Bristol-Myers Squibb Company | Catecholamine surrogates useful as β3 agonists |
US5962440A (en) | 1996-05-09 | 1999-10-05 | Bristol-Myers Squibb Company | Cyclic phosphonate ester inhibitors of microsomal triglyceride transfer protein and method |
US5885983A (en) | 1996-05-10 | 1999-03-23 | Bristol-Myers Squibb Company | Inhibitors of microsomal triglyceride transfer protein and method |
US5827875A (en) | 1996-05-10 | 1998-10-27 | Bristol-Myers Squibb Company | Inhibitors of microsomal triglyceride transfer protein and method |
PL192359B1 (pl) * | 1996-08-30 | 2006-10-31 | Novo Nordisk As | Pochodna GLP-1(7-37) lub analogu GLP-1(7-37), środek farmaceutyczny oraz zastosowanie pochodnej GLP-1(7-37) lub analogu GLP-1(7-37) |
US5760246A (en) | 1996-12-17 | 1998-06-02 | Biller; Scott A. | Conformationally restricted aromatic inhibitors of microsomal triglyceride transfer protein and method |
TW536540B (en) | 1997-01-30 | 2003-06-11 | Bristol Myers Squibb Co | Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe |
GB9713739D0 (en) | 1997-06-27 | 1997-09-03 | Karobio Ab | Thyroid receptor ligands |
WO1999003880A1 (en) | 1997-07-15 | 1999-01-28 | Novo Nordisk A/S | Nociceptin analogues |
CA2819705C (en) | 1998-02-02 | 2014-07-08 | Trustees Of Tufts College | Method of regulating glucose metabolism, and reagents related thereto |
CA2320371C (en) * | 1998-02-13 | 2012-01-17 | Amylin Pharmaceuticals, Inc. | Inotropic and diuretic effects of exendin and glp-1 |
AU3034299A (en) | 1998-03-09 | 1999-09-27 | Fondatech Benelux N.V. | Serine peptidase modulators |
FR2777283B1 (fr) * | 1998-04-10 | 2000-11-24 | Adir | Nouveaux composes peptidiques analogues du glucagon-peptide- 1 (7-37), leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
DE19823831A1 (de) | 1998-05-28 | 1999-12-02 | Probiodrug Ges Fuer Arzneim | Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen |
DE19828113A1 (de) | 1998-06-24 | 2000-01-05 | Probiodrug Ges Fuer Arzneim | Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV |
DE19828114A1 (de) | 1998-06-24 | 2000-01-27 | Probiodrug Ges Fuer Arzneim | Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV |
DE69940063D1 (de) | 1998-07-06 | 2009-01-22 | Bristol Myers Squibb Co | Biphenylsulfonamide als zweifach aktive rezeptor antagonisten von angiotensin und endothelin |
CZ2001690A3 (cs) | 1998-08-28 | 2002-04-17 | Eli Lilly And Company | Způsob podávání inzulinotropních peptidů |
US6461834B1 (en) * | 1998-11-06 | 2002-10-08 | Bionebraska, Inc. | Clostripain catalyzed amidation of peptides |
WO2000034331A2 (en) * | 1998-12-07 | 2000-06-15 | Societe De Conseils De Recherches Et D'applications Scientifiques Sas | Analogues of glp-1 |
BR9916027A (pt) | 1998-12-07 | 2001-08-28 | Sod Conseils Rech Applic | Análogos de glp-1 |
ES2343072T3 (es) * | 1999-01-14 | 2010-07-22 | Amylin Pharmaceuticals, Inc. | Exendina para la supresion del glucagon. |
CN101181236A (zh) * | 1999-01-14 | 2008-05-21 | 安米林药品公司 | 新型exendin激动剂制剂及其给药方法 |
BR0010705A (pt) * | 1999-04-30 | 2002-02-05 | Amylin Pharmaceuticals Inc | Exendinas modificadas e agonistas da exendina |
US6344180B1 (en) * | 1999-06-15 | 2002-02-05 | Bionebraska, Inc. | GLP-1 as a diagnostic test to determine β-cell function and the presence of the condition of IGT and type II diabetes |
EP1361205A1 (en) | 1999-12-13 | 2003-11-12 | Chugai Seiyaku Kabushiki Kaisha | Compounds with hydroxycarbonyl-halogenalkyl side chains |
CA2372352A1 (en) | 2000-04-07 | 2001-10-18 | Hyun-Gyu Park | Sulfonamide derivative as a matrix metalloproteinase inhibitor |
EP1695983B1 (en) * | 2000-06-16 | 2009-03-04 | Eli Lilly & Company | Glucagon-like peptide-1 analogs |
US6579889B2 (en) | 2000-06-22 | 2003-06-17 | Merck & Co., Inc. | Substituted isonipecotyl derivatives as inhibitors of cell adhesion |
IL155812A0 (en) * | 2000-12-07 | 2003-12-23 | Lilly Co Eli | Glp-1 fusion proteins |
WO2002047716A2 (en) * | 2000-12-13 | 2002-06-20 | Eli Lilly And Company | Chronic treatment regimen using glucagon-like insulinotropic peptides |
US7385025B2 (en) * | 2000-12-19 | 2008-06-10 | Palatin Technologies, Inc. | Metallopeptide compounds |
US7144863B2 (en) * | 2001-06-01 | 2006-12-05 | Eli Lilly And Company | GLP-1 formulations with protracted time action |
US7238671B2 (en) * | 2001-10-18 | 2007-07-03 | Bristol-Myers Squibb Company | Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions |
PL377687A1 (pl) | 2001-10-18 | 2006-02-06 | Bristol-Myers Squibb Company | Środki naśladujące ludzki peptyd glukagonopodobny typu 1 i ich zastosowanie w leczeniu cukrzycy i stanów związanych z cukrzycą |
TW200611704A (en) * | 2004-07-02 | 2006-04-16 | Bristol Myers Squibb Co | Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions |
US7145040B2 (en) * | 2004-07-02 | 2006-12-05 | Bristol-Myers Squibb Co. | Process for the preparation of amino acids useful in the preparation of peptide receptor modulators |
-
2002
- 2002-10-18 PL PL377687A patent/PL377687A1/pl not_active Application Discontinuation
- 2002-10-18 CA CA002463908A patent/CA2463908A1/en not_active Abandoned
- 2002-10-18 JP JP2003536401A patent/JP2005514337A/ja active Pending
- 2002-10-18 CN CNA028205588A patent/CN1630709A/zh active Pending
- 2002-10-18 EP EP02782185A patent/EP1572892A4/en not_active Withdrawn
- 2002-10-18 KR KR10-2004-7005731A patent/KR20040054729A/ko not_active Application Discontinuation
- 2002-10-18 NZ NZ531788A patent/NZ531788A/en unknown
- 2002-10-18 IL IL16091702A patent/IL160917A0/xx unknown
- 2002-10-18 HU HU0700151A patent/HUP0700151A2/hu unknown
- 2002-10-18 WO PCT/US2002/033386 patent/WO2003033671A2/en active Search and Examination
- 2002-10-18 BR BRPI0213377-6A patent/BR0213377A/pt not_active IP Right Cessation
- 2002-10-18 GE GE5582A patent/GEP20063908B/en unknown
- 2002-10-18 AU AU2002348469A patent/AU2002348469B2/en not_active Ceased
- 2002-10-18 US US10/273,975 patent/US7238670B2/en not_active Expired - Lifetime
- 2002-10-18 MX MXPA04003553A patent/MXPA04003553A/es active IP Right Grant
- 2002-10-18 YU YU31004A patent/YU31004A/sh unknown
- 2002-10-18 RU RU2004114836/04A patent/RU2353625C2/ru not_active IP Right Cessation
-
2004
- 2004-03-16 IS IS7185A patent/IS7185A/is unknown
- 2004-03-23 NO NO20041203A patent/NO20041203L/no not_active Application Discontinuation
- 2004-04-15 HR HR20040343A patent/HRP20040343A2/hr not_active Application Discontinuation
- 2004-04-15 ZA ZA200402846A patent/ZA200402846B/en unknown
-
2007
- 2007-04-25 US US11/740,031 patent/US20070287670A1/en not_active Abandoned
-
2010
- 2010-04-30 US US12/771,096 patent/US20100210552A1/en not_active Abandoned
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107080836A (zh) * | 2009-07-06 | 2017-08-22 | 赛诺菲-安万特德国有限公司 | 含有甲硫氨酸的水性胰岛素制备物 |
CN102250315A (zh) * | 2011-05-10 | 2011-11-23 | 郑州大学 | 氨基酸衍生环氧树脂 |
CN102920658A (zh) * | 2012-11-02 | 2013-02-13 | 艾韦特(溧阳)医药科技有限公司 | 与glp-1类似物和聚乙二醇结合的脂质体及其制备方法 |
CN105683153A (zh) * | 2013-09-17 | 2016-06-15 | 维克图斯生物系统有限公司 | 用于治疗高血压和/或纤维化的组合物 |
CN105683153B (zh) * | 2013-09-17 | 2018-07-13 | 维克图斯生物系统有限公司 | 用于治疗高血压和/或纤维化的组合物 |
WO2021238965A1 (zh) * | 2020-05-28 | 2021-12-02 | 杭州中美华东制药有限公司 | (s)-2-氨基-3-(4-(2,3-二甲基吡啶-4-基)苯基丙酸甲酯及其盐的制备方法 |
CN115697968A (zh) * | 2020-05-28 | 2023-02-03 | 杭州中美华东制药有限公司 | (s)-2-氨基-3-(4-(2,3-二甲基吡啶-4-基)苯基丙酸甲酯及其盐的制备方法 |
CN115697968B (zh) * | 2020-05-28 | 2024-03-29 | 杭州中美华东制药有限公司 | (s)-2-氨基-3-(4-(2,3-二甲基吡啶-4-基)苯基丙酸甲酯及其盐的制备方法 |
CN114591418A (zh) * | 2020-12-04 | 2022-06-07 | 南京大学 | PPARγ蛋白的第166位苏氨酸磷酸化修饰及其应用 |
Also Published As
Publication number | Publication date |
---|---|
CA2463908A1 (en) | 2003-04-24 |
MXPA04003553A (es) | 2004-07-22 |
IS7185A (is) | 2004-03-16 |
RU2353625C2 (ru) | 2009-04-27 |
HUP0700151A2 (en) | 2007-05-29 |
KR20040054729A (ko) | 2004-06-25 |
ZA200402846B (en) | 2005-08-16 |
NO20041203L (no) | 2004-06-10 |
JP2005514337A (ja) | 2005-05-19 |
PL377687A1 (pl) | 2006-02-06 |
GEP20063908B (en) | 2006-08-25 |
RU2004114836A (ru) | 2005-04-10 |
HRP20040343A2 (en) | 2005-08-31 |
IL160917A0 (en) | 2004-08-31 |
WO2003033671A3 (en) | 2005-12-29 |
EP1572892A2 (en) | 2005-09-14 |
US7238670B2 (en) | 2007-07-03 |
US20070287670A1 (en) | 2007-12-13 |
EP1572892A4 (en) | 2007-08-22 |
US20100210552A1 (en) | 2010-08-19 |
US20030195157A1 (en) | 2003-10-16 |
WO2003033671A2 (en) | 2003-04-24 |
YU31004A (sh) | 2006-08-17 |
BR0213377A (pt) | 2006-05-23 |
NZ531788A (en) | 2008-01-31 |
AU2002348469B2 (en) | 2008-03-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1630709A (zh) | 人胰高血糖素样多肽-1模拟物和它们在治疗糖尿病和相关状况中的应用 | |
US7417028B2 (en) | Human glucagon-like-peptide-1 modulators and their use in treatment of diabetes and related conditions | |
US7960349B2 (en) | N-terminally modified GLP-1 receptor modulators | |
US7238671B2 (en) | Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions | |
CN101282991A (zh) | N-端修饰的胰高血糖素样肽-1受体调节剂 | |
US20070238669A1 (en) | Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes related conditions | |
AU2002348469A1 (en) | Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions | |
CN1347327A (zh) | 抑制胰高血糖素的方法 | |
CN101010339B (zh) | 人类胰高血糖素样肽-1调节剂及它们在治疗糖尿病及相关病况中的用途 | |
CN101400699A (zh) | 人胰高血糖素样肽-1调节剂及其在治疗糖尿病和相关病症中的用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CI01 | Publication of corrected invention patent application |
Correction item: Inventor Correct: Tino Joseph A. False: (sixth W - R - inventor) for you Number: 25 Volume: 21 |
|
CI02 | Correction of invention patent application |
Correction item: Inventor Correct: Tino Joseph A. False: (sixth W - R - inventor) for you Number: 25 Page: The title page Volume: 21 |
|
COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: (NO. 6 INVENTOR) W R EWING TO: TINO JOSEPH A. |
|
ERR | Gazette correction |
Free format text: CORRECT: INVENTOR; FROM: (NO. 6 INVENTOR) W R EWING TO: TINO JOSEPH A. |
|
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |